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 The brainstem and prefrontal cortex (PFC) are known to play important 
roles in pain, and could be involved in different phases of pain processing. 
The brainstem is known to receive nociceptive information and involved in the 
descending pain inhibitory system, while the prefrontal cortex is important in 
the cognitive control of pain. The present study was carried out using 
microarray-based approaches to examine gene expression and miRNA 
changes in the brainstem and prefrontal cortex in a mouse facial carrageenan 
injection model of orofacial pain. 
At the brainstem level, increased expression of genes related to 
“leukocyte adhesion” i.e. Selp and Icam-1 were observed in the mice 
brainstems three days after facial carrageenan injection. It is proposed that 
facial carrageenan injection-induced inflammation results in the release of 
CCL12 into the bloodstream of the brainstem, and attracts leukocytes to the 
endothelial cells of blood vessel. At the same time, inflammation causes 
upregulation of P-selectin and ICAM-1 on the surface of endothelial cells in 
the brainstem. This facilitates transmigration of leukocytes into the brainstem 
or CNS, releasing pro-nociceptive substances such as nitric oxide, 
superoxide, or peroxynitrite, resulting in orofacial pain. The use of P-selectin 
inhibitor, KF38789 demonstrated a decrease in pain behavioral response of 
facial carrageenan injected mice, possibly via the inhibition of leukocytes 








 At the prefrontal cortex level, increased expression of miRNAs related 
to inflammatory diseases and immune responses i.e. mmu-miR-155, and -223 
were observed in the PFC three days after facial carrageenan injection. 
Inflammation was detected in the PFC, with increased levels of MPO-positive 
cells observed in the PFC of mice, three days after facial carrageenan 
injection. Inflammation in the PFC was accompanied by increased levels of 
immune response-related genes, including S100a8, S100a9, Lcn2, Il2rg, 
Fcgrl, Fcgr2b, C1qb, Ptprc, Ccl12 and Cd52. This increase in immune 
response may result in activation of PFC, and decrease in pain perception via 
the descending pain inhibitory system. In addition, intracortical injection of 
mS100A9p into the PFC showed a decreased in pain response 12 hr after 
administration, suggesting an antinociceptive role of S100A9 in the PFC. 
Together, the increased immune activity and the increased expression of 
S100A9 may facilitate antinociception. 
The present studies demonstrated the involvement of both brainstem 
and prefrontal cortex in pain, in a mouse model of orofacial pain. The 
differentially expressed genes in different region of the brain i.e. brainstem 
and PFC could play different roles in pain and contribute to different part of 
the pain system. The use of KF38789 in inhibiting P-selectin and the use of 
mS100A9p to mimic S100A9 in the prefrontal cortex, showed remarkable 
reduction in nociceptive response. Thus, by targeting molecules that are 
involved in the pain system, it is possible to alleviate pain. 
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Pain is defined as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of 
such damage” according to the International Association for the Study of Pain 
(IASP) (Bonica, 1979). It also motivates us to withdraw from potential threats 
or source of the pain, and protect the damaged body part while it heals. 
Pain is always subjective because each individual learns the 
application of the word through experiences related to injury in early life. It is 
this experience that we associate with actual or potential tissue damage. Pain 
is due to a sensation in an area or areas of the body. It is always unpleasant 
and thus also an emotional experience. There are cases where people report 
pain in the absence of tissue damage or any likely pathophysiological cause. 
This usually happens for psychological reasons. If these patients regard their 
experience as pain and report it in the same ways as pain caused by tissue 
damage, it should by accepted as pain. This definition, however, avoids 
associating pain to the stimulus (Bonica, 1979). 
Nociception is the neural process of encoding and processing noxious 
stimuli (Loeser and Treede, 2008). It is also refers to as noxious stimulus 
originating from the sensory receptors where this information is carried into 
the central nervous system (CNS) by the primary afferent neuron (Okeson 
and Bell, 2005). The term nociception should not be confused with pain, 
because each can exist without the other (Loeser and Treede, 2008). Two of 
the most commonly used terms in the pain research are hyperalgesia and 






allodynia. Hyperalgesia is an increased in response to a stimulus that is 
normally painful. On the other hand, pain resulting from a stimulus that does 
not normally provoke pain is called allodynia (Merskey et al., 1994). Other 
pain-related terms are listed in table 1. 
Term Definition 
Noxious stimulus An actually or potentially tissue damaging event 
Nociceptor A sensory receptor that is capable of transducing and encoding noxious stimuli 
Neuropathic pain Pain arising as a direct consequence of a lesion or disease affecting the somatosensory system 
Sensitization Increased responsiveness of neurons to their normal input or recruitment of a response to normally subthreshold inputs 
Peripheral sensitization Increased responsiveness and reduced threshold of nociceptors to stimulation of their receptive fields 
Central sensitization Increased responsiveness of nociceptive neurons in the central nervous system to their normal or subthreshold afferent input 
Pain threshold The minimal intensity of a stimulus that is perceived as painful 
Hyperesthesia Increased sensitivity to stimulation, excluding the special senses 
Hyperpathia 
A painful syndrome characterized by an abnormally painful 
reaction to a stimulus, especially a repetitive stimulus, as well as 
an increased threshold. 
Neuropathy 
 
A disturbance of function or pathological change in a nerve: in 
one nerve, mononeuropathy; in several nerves, mononeuropathy 
multiplex; if diffuse and bilateral, polyneuropathy. 
 
Table 1.1. Other pain-related terms and definitions. Modified from Loeser and Treede, 2008. 
 
1.1. Hyperalgesia and allodynia 
 The difference between hyperalgesia and allodynia can be explained in 
terms of pain hypersensitivity. In hyperalgesia, the responsiveness is 
increased, so that noxious stimuli produce an exaggerated and prolonged 
pain. In allodynia, the thresholds are lowered so that stimuli that would 
normally not produce pain now begin to induce pain (Woolf and Mannion, 
1999; Woolf and Salter, 2000). 






 In psychophysical terms, hyperalgesia and allodynia are best 
understood as a result of a leftward shift in the curve that relates stimulus 
intensity to pain sensation, following a peripheral injury (Figure 1.1). This shift 
causes the lower region of the curve to fall in the innocuous stimulus intensity 
range (allodynia) whereas the top region demonstrates an increased pain 
sensation to noxious stimuli (hyperalgesia) (Cervero and Laird, 1996). 
 
Figure 1.1. Diagram illustrating the changes in pain sensation induced by injury. 
The normal relationship between stimulus intensity and the magnitude of pain 
sensation is represented by the curve at the right-hand side of the figure. Pain 
sensation is only evoked by stimulus intensities in the noxious range (the vertical 
dotted line indicates the pain threshold). Injury provokes a leftward shift in the 
curve relating stimulus intensity to pain sensation. Under these conditions, 
innocuous stimuli evoke pain (allodynia). Adapted from Cervero and Laird, 1996. 
 
1.2. Neural pathways of pain 
 The neural pathways of pain involve four distinct processes: 
transduction, transmission, modulation, and perception (Fields, 1987). 
Transduction is the process by which noxious stimuli lead to electrical activity 
in the appropriate nerve endings (Okeson and Bell, 2005).  






The second process, transmission, is the neural events that carry the 
nociceptive input into the CNS for proper processing. This transmission 
system comprises of three basic components. The first is the peripheral 
sensory nerve: the primary afferent neuron. This neuron carries the 
nociceptive input from the sensory organ into the spinal cord. The second 
component of the transmission process, second-order neuron, carries the 
input to the higher centers. This portion of the transmission process involves 
several neurons that interact as the input is sent up to the thalamus. The third 
component of the transmission system represents interaction of neurons 
between the thalamus, the cortex, and the limbic system as the nociceptive 
input reaches these higher centers (Okeson and Bell, 2005).  
The third process, modulation, refers to the ability of the CNS to control 
the pain-transmitting neurons. Several areas of the cortex and brainstem have 
been identified to either enhance or reduce nociceptive input arriving via way 
of the transmitting neurons (Okeson and Bell, 2005). 
The final process, perception, occurs when the nociceptive input 
reaches the cortex. This immediately initiates a complex interaction of 
neurons between the higher centers of the brain. It is at this point that 
suffering and pain behavior begin. This is the least understood aspect of pain 
and the most variable between individuals (Okeson and Bell, 2005). 
 






1.3. Types of pain 
 There are several types of pain depending on the source of pain and 
nature of the stimuli. The two major types of pain are nociceptive pain and 
neuropathic pain. Other types of pain include inflammatory pain and 
psychogenic pain. However, it is important to know that these types of pain 
are not exclusive. 
 
1.3.1. Nociceptive pain 
 Nociceptive pain is mediated by receptors on A-delta and C nerve 
fibers (Fishman et al., 2010), which are located in skin, bone, connective 
tissue, muscle and viscera. These receptors play important roles at localizing 
noxious chemical, thermal and mechanical stimuli. Nociceptive pain can be 
somatic or visceral in nature. Somatic pain tends to be well-localized, with 
constant pain that is described as sharp, aching, and throbbing. On the other 
hand, visceral pain tends to be vague in distribution, spasmodic in nature and 
is usually described as deep, aching, squeezing and colicky in nature. 
Examples of nociceptive pain include: post-operative pain, pain associated 
with trauma, and the chronic pain of arthritis (Omoigui, 2007). 
 
1.3.2. Neuropathic pain 
 Neuropathic pain arises as a result of a lesion or disease affecting the 
somatosensory system (Treede et al., 2008). It is caused by damage to or 
malfunction of the nervous system, and can be categorized into "peripheral" - 
originating in the peripheral nervous system and "central" - originating in the 






CNS (Treede et al., 2008). Neuropathic pain, in contrast to nociceptive pain, is 
described as "burning", "electric", "tingling", and "shooting" in nature. 
Examples of neuropathic pain include: carpal tunnel syndrome, trigeminal 
neuralgia, post herpetic neuralgia, and the various peripheral neuropathies 
(Omoigui, 2007). 
 
1.3.3. Inflammatory pain 
 Tissue injury initiates an inflammatory response that induces pain. This 
type of pain is known as inflammatory pain. Inflammatory pain is due mainly to 
the action of prostaglandins and bradykinin, and substances released during 
the inflammatory process (Okeson and Bell, 2005). Together, they act to 
increase local vasodilation and capillary permeability as well as alter the 
sensitivity and receptivity of receptors in the area (Lim, 1970; Hedenberg-
Magnusson et al., 2001). Thus, the pain threshold is lowered so that 
nociceptors become more sensitive to stimulation, and higher-threshold 
mechanoreceptors are sensitized to wider variety of stimuli, resulting in pain 
hypersensitivity which takes the form of allodynia and hyperalgesia (Kidd and 
Urban, 2001).  
 
1.3.4. Pyschogenic pain 
 Psychogenic pain or psychalgia, is a physical pain that is caused by 
some underlying psychological disorder, rather than some immediate physical 
injury. It is a form of chronic pain that may be linked to stress, unexpressed 
emotional conflicts, psychosocial problems, or various mental disorders. It is 






named psychogenic pain because no structural condition could be found to 
explain the pain. Examples of pyschogenic pain include: headache, back pain, 
or stomach pain. 
 
1.4. Sensitization 
 Sensitization is an increased response of neurons / neuronal 
responsiveness to a variety of inputs following intense or noxious stimuli. 
Sensitization once developed may last for long periods and is characterized 
by enhanced responses to even weaker stimuli (Baranauskas and Nistri, 
1998). In short, it is an increase in the excitability of neurons, so they are 
more sensitive to stimuli or sensory inputs. Sensitization is one of the simplest 
forms of learning and synaptic plasticity, and is an important feature of 
nociception (Kandel et al., 1991). Two forms of sensitization – peripheral and 
central sensitization are known to be involved in pain hypersensitivity. 
 
1.4.1. Peripheral sensitization 
 Peripheral sensitization is a decrease in threshold and an increase in 
sensitivity and excitability of the nociceptor terminals. It is also the 
predominant cause of primary hyperalgesia - an increased sensitivity within 
the injured area (Treede et al., 1992; Strong, 2002; Walker et al., 2007). 
Peripheral sensitization occurs when nociceptor terminals become exposed to 
products of tissue injury and inflammation that are released following a nerve 
injury, resulting in altered expression and distribution of ion channels in the 
nociceptor	   terminals (Julius and Basbaum, 2001; Okeson and Bell, 2005). 






Products of tissue damage and inflammation are normally inflammatory 
mediators such as prostaglandin E2 (PGE2), bradykinin and nerve growth 
factor (NGF). These chemicals interact with G-protein-coupled receptors or 
tyrosine kinase receptors expressed on nociceptor terminals, activating 
intracellular signaling pathways that alter the threshold and kinetics of 
receptors and ion channels in the nociceptor terminal. This increases the 
sensitivity and excitability of the nociceptor terminals (Julius and Basbaum, 
2001; Ji et al., 2003). 
Peripheral sensitization leads to an ongoing burst of nociceptive input, 
which causes the subsequent release of tachykinins such as substance P and 
neurokinin A. These neuropeptides interact with neurokinin receptors in the 
second-order neurons and trigger the release of intracellular calcium, 
facilitating the up-regulation of the N-methyl-D-aspartate (NMDA) receptors 
(Torebjork et al., 1992; Yu et al., 1996; Ren and Dubner, 1999). These leads 
to the release of excitatory amino acids such as aspartate and glutamate into 
the synapse between the primary and secondary neuron (Woolf and 
Thompson, 1991; Coderre et al., 1993), resulting in further influx of calcium 
into the cell. This intracellular calcium results in a cascade of enzymatic 
activity and genetic effects that have long-term consequences, such as 
lowering the threshold of spinal tract neurons. This lowering of the threshold 
results in what is known as central sensitization (Okeson and Bell, 2005). 
 






1.4.2. Central sensitization 
  Central sensitization is an increase in the excitability of neurons within 
the CNS, so that normal inputs begin to produce abnormal responses. It is 
originally described as an immediate-onset, activity- or use-dependent 
increase in the excitability of nociceptive neurons (neurons responsive to 
nociceptor inputs) in the dorsal horn of the spinal cord, as a result of, and 
outlasting, a short barrage of nociceptor input (Woolf, 1983; Woolf and Wall, 
1986; Cook et al., 1987). It is also the cause of secondary hyperalgesia - an 
increased sensitivity in the surrounding uninjured area (Treede et al., 1992; 
Strong, 2002; Walker et al., 2007).  
 Central sensitization is initiated by prolonged or strong activity of dorsal 
horn neurons caused by repeated or sustained noxious stimulation that lead 
to reductions in threshold and increases in the responsiveness of dorsal horn 
neurons, as well as by enlargement of their receptive fields (Cook et al., 1987; 
Meeus and Nijs, 2007). There can also be an induction of early gene 
expression that causes release of proto-oncogenes such as c-fos and c-jun 
(Abbadie et al., 1994). These substances released by the cell, alters 
messenger RNA (mRNA), which changes the type and number of receptors 
that are formed on the cell membrane, resulting in changes in cellʼs function. 
This condition is called neuroplasticity (Okeson and Bell, 2005). In addition, 
neuroplasticity and subsequent central sensitization alters the function of 
chemical, electrophysiological, and pharmacological systems (Wall et al., 
1994; DeLeo and Winkelstein, 2002; Winkelstein, 2004). These changes 






cause exaggerated perception of painful stimuli (hyperalgesia), as well as 
perception of innocuous stimuli as painful (allodynia) (Meeus and Nijs, 2007). 
 
1.5. Pain pathway from the body 
Pathways that are responsible for pain originating from the body 
involve the first-order neurons that conduct input from the periphery into the 
dorsal horn of the spinal cord or CNS via the dorsal roots. Once within the 
dorsal horn, the first-order neurons synapse with the second-order neurons, 
which travel along the spinothalamic pathway of the anterolateral system and 
ascend to higher centers (thalamus and cortex) of the CNS. The third- and 
fourth-order neurons (interneurons) carry impulses through a multisynaptic 
path to the thalamus, reticular formation, other parts of brainstem, and other 
brain structures such as the cerebellum, superior colliculus, pontine 
parabrachial nucleus, and periaqueductal gray matter (PAG) (Sessle, 2000; 
de Leeuw et al., 2005). The ascending pain pathway involves 2 main 
pathways: the lateral and the medial pain system (de Leeuw et al., 2005). The 
lateral pain system also known as the neospinothalamic tract relays 
information to the ventral posterior lateral nucleus, ventral posterior medial 
nucleus, and ventral posterior inferior nucleus of the thalamus (de Leeuw et 
al., 2005). The lateral thalamic nuclei project to the primary (SI) and 
secondary (SII) somatosensory cortices and are thought to mediate the 
sensory-discriminative aspects of facial pain (de Leeuw et al., 2005). 
Activation of the contralateral brain is observed when stimulus travels through 
the lateral pain system (Treede et al., 1999; Rome and Rome, 2000). The 






medial pain system, or paleospinothalamic tract, mainly involves medial 
thalamic structures, such as the ventral part of the ventral medial nucleus, the 
ventrocaudal part of the medial dorsal nucleus, the intralaminar nucleus, and 
the contralateral nucleus. The medial thalamic nuclei send information to the 
insula and anterior cingulate cortex (ACC), and comprises the affective and 
motivational aspects of facial pain (de Leeuw et al., 2005). The medial pain 
system possesses spinothalamic and spinoreticular projections to various 
brainstem nuclei and the limbic structures (Wall et al., 1994). From the limbic 
system, the nociceptive stimulus is conducted to both right and left cerebral 
cortices, suggesting a bilateral activation (de Leeuw et al., 2005). Several 
other cortico-cortical connections may also be important in the pain pathways 
(Treede et al., 1999). Thus, limiting the pain pathways into a lateral and a 
medial system is much too simplistic (de Leeuw et al., 2005). A diagram of the 
ascending pain pathway is illustrated in Figure 1.2. 
 
 







Figure 1.2. Major pathways for pain sensation from the body. 
Adapted from Purves and Williams, 2001. 
 






2. Orofacial pain 
 Orofacial pain is defined by the American Academy of Orofacial Pain 
(AAOP) as “pain conditions that are associated with the hard and soft tissues 
of the head, face, neck, and all of the intraoral structures” (Okeson, 1996). It is 
a dysfunction affecting the sensory and motor functions of the trigeminal 
nerve system and the structures it innervates (Renton, 2008). The trigeminal 
nerve takes up the bulk of the sensory cortex of the human mind, which 
explains the highly distressing nature of pain in these regions (Renton, 2008). 
 Common orofacial pain conditions include toothache, periodontal pain, 
oral soft tissue pain and headache. Other conditions include 
temporomandibular disorders (TMDs), characterized by pain in the 
temporomandibular joint (TMJ) and / or the associated muscles of mastication 
(Sessle, 2008). TMD pain is the most common chronic orofacial pain 
condition, and its intensity, persistence and psychologic impact is similar to 
that of back pain (Von Korff et al., 1988). Trigeminal neuralgia is head or face 
pain characterized by sudden, brief paroxymal stabbing pain along one or 
more distributions of the trigeminal nerve, and is less common than TMDs 
(Sessle, 2008). Dysesthesias is characterized by burning pain or discomfort in 
the oral soft tissues, e.g. burning mouth syndrome (BMS) (Sessle, 2008). 
 
2.1. Trigeminal system 
 Somatic sensation of the head and oral cavity is carried by four cranial 
nerves: the trigeminal nerve which is the most important of the four nerves 
(innervates most of the head and oral cavity); the facial, glossopharyngeal 






and the vagus nerves (innervate the skin of the external ear, pharynx, nasal 
cavity and middle ear) (Strong, 2002). Unlike the common pathways 
described earlier, somatic input from the face and oral structures does not 
enter the spinal cord via the spinal nerves. Instead, sensory input from the 
face and mouth is carried via the fifth cranial nerve, the trigeminal nerve 
(Okeson and Bell, 2005). The trigeminal nerve provides sensory innervations 
to the face and structures in the oral and nasal cavities. In addition, its motor 
component innervates the muscles of mastication and other skeletal muscles. 
Fine (discriminatory) tactile, general (light) tactile, proprioceptive, thermal, and 
pain sensory modalities are conveyed to the brainstem trigeminal nuclei 
(Conn, 2008). Axons from the sensory trigeminal nuclei contribute to important 
reflex circuits and relay sensory modalities to the thalamus for further 
integration. (Conn, 2008).  
 
2.1.1. Trigeminal nerve 
 The trigeminal nerve has three major peripheral branches, the 
opthalmic, the maxillary and the mandibular nerves (Figure1.3). The 
trigeminal nerve is the main mediator of somatic sensation from the mouth 
and face. It innervates the face superficially in the region forward of a line 
drawn vertically from the ears across the top of the head and superior to the 
level of the lower border of the mandible. Impulses carried by the trigeminal 
nerve enter directly into the brainstem in the region of the pons to synapse in 
the trigeminal spinal tract nucleus. This region of the brainstem is the 






functional equivalent of the dorsal horn of the spinal cord (Okeson and Bell, 
2005). 
 
Figure 1.3. Diagrammatic representation of the superficial sensory distribution of 
the trigeminal nerve: the ophthalmic division (V1), the maxillary division (V2), and 
mandibular division (V3). Adapted from Okeson and Bell, 2005.  
 
2.1.2. Trigeminal ganglion 
The trigeminal (Gasserian or semilunar) ganglion is a sensory nerve 
ganglion that contains the cell bodies of incoming sensory fibers, and is also 
where the three branches of the trigeminal nerve converge (Barker, 2002). 
The trigeminal ganglion resides in a cavity, called Meckelʼs cave in the dura 
mater covering the trigeminal impression near the apex of the petrous part of 
the temporal bone (Gray and Clemente, 1985). The trigeminal ganglion is 
responsible for processing the sensory aspects of the trigeminal nerve, as in 






the sensations of touch or pressure. It is analogous to the dorsal root ganglia 
of the spinal cord, which contain the cell bodies of incoming sensory fibers 
from the rest of the body (Squire, 2008). 
 
2.1.3. Trigeminal nerve nuclei 
The trigeminal nerve has four nuclei: (1) the main (or principal) sensory 
trigeminal nucleus, (2) the spinal trigeminal nucleus, (3) the mesencephalic 
trigeminal nucleus, and (4) the trigeminal motor nucleus (Figure 1.4) (Snell, 
2010). The main sensory nucleus, spinal nucleus and mesencephalic nucleus 
are known as sensory trigeminal nuclei, which serve the somatic sensation 
(e.g. from the face) from the cranial nerves. These sensory fibers terminate in 
two of the sensory trigeminal nuclei, the main sensory trigeminal nucleus and 
the spinal trigeminal nucleus. The third sensory nucleus, the mesencephalic 
trigeminal nucleus, is not a site of termination of primary sensory fibers. 
Rather, it is equivalent to a peripheral sensory ganglion because it contains 
the cell bodies of certain trigeminal primary sensory fibers (Martin, 2003). 
 
 







Figure 1.4. Lateral view of the brainstem, indicating the locations of trigeminal nuclei (bold). 
Adapted from Kamel and Toland, 2001. 
 
Main sensory trigeminal nucleus 
The main sensory trigeminal nucleus is located in the pons and 
receives information of the primary sensory neurons transmitting touch / 
position sensation from the face and mouth (Monkhouse, 2006). The primary 
sensory neurons then synapse with the cell bodies of the secondary sensory 
neurons. From the main trigeminal nucleus, secondary fibers cross the 
midline and ascend in the trigeminal lemniscus to the contralateral thalamus, 
in its ventral posterior medial nucleus (Martin, 2003; Monkhouse, 2006). 
Axons from the thalamic neurons then projects via the posterior limb of the 
internal capsule to the lateral part of the primary somatic sensory cortex, in 
the postcentral gyrus (Martin, 2003). In addition, a small proportion of fibers 
that originate from the dorsal portion of the main trigeminal sensory nucleus 
may ascends ipsilaterally to the ventral posterior medial nucleus and 






processes mechanical stimuli from the teeth and soft tissues of the oral cavity 
(Martin, 2003). 
 
Spinal trigeminal nucleus 
 The spinal trigeminal nucleus is located in the medulla and extends 
down into the cervical spinal cord (Martin, 2003; Monkhouse, 2006). Similar to 
the dorsal horn of the spinal cord, the spinal trigeminal nucleus plays an 
essential role in facial and dental pain, temperature sensation and itch, 
receiving information transmitting pain / temperature sensation from the face 
(Martin, 2003). From the spinal trigeminal nucleus, secondary fibers cross the 
midline and ascend in the trigeminal lemniscus to the contralateral thalamus, 
in three principal locations: the ventral posterior medial nucleus, the 
ventromedial posterior nucleus and the medial dorsal nucleus (Martin, 2003; 
Monkhouse, 2006). The ventral posterior medial nucleus projects to the 
primary somatic sensory cortex in the lateral part of the postcentral gyrus, and 
the ventromedial posterior nucleus projects to the insular cortex (Martin, 
2003). These projections from the ventromedial posterior nucleus to the 
insular cortex are involved in the perception of temperature, pain and itch. The 
medial dorsal nucleus projects to the anterior cingulate gyrus. Both the insular 
cortex and the anterior cingulate gyrus are known to participate in the affective 
and motivational aspects of facial pain, itch, and temperature senses (Martin, 
2003). 
The spinal trigeminal nucleus is divided into three parts, from rostral to 
caudal: the nucleus interpolaris, the nucleus oralis, and the nucleus caudalis 






(Okeson and Bell, 2005). The nucleus interpolaris is located in the mid-
medulla and caudal pons and plays a role in mediating sensation from the 
teeth (Strong, 2002; Conn, 2008). The nucleus oralis is anatomically 
continuous with the principal sensory trigeminal nucleus and is thought to be 
involved with discriminative touch sensation (Strong, 2002; Conn, 2008). The 
nucleus caudalis is found in the caudal medulla (Conn, 2008). It mediates 
facial sensation and plays an important role in pain and temperature senses, 
including dental pain, and a lesser role in tactile sensation. The caudalis 
nucleus is sometimes called the medullary dorsal horn because its laminar 
organization is similar to that of the spinal dorsal horn (Dubner and Bennett, 
1983; Strong, 2002; Martin, 2003). 
 
Mesencephalic trigeminal nucleus 
The mesencephalic trigeminal nucleus is located in the lower midbrain 
and receives impulses transmitting proprioceptive information from 
masticatory muscles, and deep pressure sensation from the teeth and gums 
(Monkhouse, 2006). The trigeminal mesencephalic nucleus projects the 
proprioceptive information to the cerebellum, activating reflex functions 
associated with salivation, chewing, swallowing, and tongue movements 
(Conn, 2008).  Unlike all other sensory fibers, which have their cell bodies in 
the peripheral ganglion, the mesencephalic nucleus houses the primary 
sensory neuron cell bodies (Monkhouse, 2006). It is also the only structure in 
the CNS to contain the cell bodies of a primary sensory neuron (Conn, 2008). 
 






Motor trigeminal nucleus 
The trigeminal motor nucleus is located in the lateral tegmentum of the 
mid-pons and lies ventromedial to the principal sensory trigeminal nucleus 
(Conn, 2008). The trigeminal motor nucleus consists mostly of large and 
some small multipolar neurons. The larger neurons are the lower motor 
neurons for the skeletal muscles innervated by the trigeminal nerve, and they 
participate in important reflexes and other responses (Conn, 2008). The 
smaller neurons are interneurons associated with regulation of trigeminal 
motor functions (Conn, 2008). 
 
2.2. Pain pathway from the orofacial region 
 Information about noxious and thermal stimulation of the face 
originates from first-order neurons that are located in the trigeminal ganglion 
and from ganglia associated with cranial nerves VII, IX, and X (Purves and 
Williams, 2001). After entering the pons, the trigeminal fibers descend to the 
medulla, forming the spinal trigeminal tract (or spinal tract of the cranial nerve 
V) and terminate in two subdivisions of the spinal trigeminal complex: the 
nucleus interpolaris, and the nucleus caudalis (Purves and Williams, 2001). 
Axons from second-order neurons in these two trigeminal nuclei cross the 
midline and terminate in a variety of targets in the brainstem and thalamus 
(Purves and Williams, 2001). 
The ascending trigeminal pathway, which is important for facial pain, 
starts at the spinal trigeminal nucleus, especially the caudal and interpolar 
nuclei, and terminates in the contralateral thalamus (Martin, 2003). The 






organization of this path is similar to that of the spinothalamic tract. This 
ascending trigeminothalamic tract is predominantly crossed and ascends with 
fibers of the anterolateral system (Martin, 2003). Subcomponents terminate in 
two locations in the thalamus: laterally, in the ventral posterior medial nucleus, 
and medially, in the intralaminar nuclei. Similar to the pain pathway from the 
body, projections of these two thalamic sites mediate different aspects of pain. 
The projection to the ventral posterior medial nucleus is thought to mediate 
discriminative aspects of facial pain. In contrast, the projection to the 
intralaminar nuclei is thought to participate in the affective and motivational 
aspects of facial pain (Martin, 2003). There is a further parallel between the 
trigeminal and spinal ascending systems: The ventral posterior medial 
nucleus projects to the facial representation of the primary and secondary 
somatic sensory cortex and the intralaminar nuclei have a more diffuse 
projection, which includes the insular cortex and anterior cingulate cortex. The 
spinal trigeminal nucleus, like the dorsal horn, also contains cells that project 
to other brain regions (Martin, 2003). A diagram of the ascending pain 
pathway of orofacial pain is illustrated in Figure 1.5. 







Figure 1.5. Major pathways for pain sensation of the trigeminal pain 
system, which carries information about these sensations from the 
face. Adapted from Purves and Williams, 2001. 
 
2.3. Descending pain inhibitory pathway 
The descending pain inhibitory pathways originates from the brainstem 
(Martin, 2003), and relay through a number of brainstem nuclei (Pertovaara 






and Almeida, 2006), and affect all sensory inputs ascending into the 
brainstem (Okeson and Bell, 2005). The descending pain inhibitory system 
also known as the analgesic system comprises of three major components: 
the periaqueductal gray matter, the nucleus raphe magnus (NRM), and a 
group of descending neurons that terminate in the substantia gelatinosa of the 
spinal tract nucleus and dorsal horn (Okeson and Bell, 2005). The descending 
pain inhibitory pathways are mainly mediated by the PAG. The PAG is a 
midbrain territory that surrounds the cerebral aqueduct and has a high 
concentration of neurotransmitter-producing neurons that can modulate 
nociceptive impulses (Okeson and Bell, 2005; Merker, 2007). The PAG is a 
key structure in relaying descending pain modulation via nuclei of the 
rostroventral medulla (RVM; nucleus raphe magnus and nucleus 
gigantocellularis pars alpha) and nuclei of the dorsolateral pontine tegmentum 
(DLPT; locus ceruleus and A7 catecholamine cells) to the spinal and 
trigeminal dorsal horn (Fishman et al., 2010). Excitatory neurons of the PAG 
matter project to the raphe nuclei in the medulla. These raphe neurons use 
serotonin as their neurotransmitter and project to the dorsal horn of the spinal 
cord, suppressing pain transmission in the dorsal horn (1) by directly inhibiting 
ascending projection neurons that transmit information about painful stimuli to 
the brain and (2) by exciting inhibitory interneurons in the dorsal horn, which 
use the neurotransmitter enkephalin (Martin, 2003). Other regions in the 
brainstem, including locus ceruleus and the lateral medullary reticular 
formation, also give rise to a descending noradrenergic projection that 






suppresses pain transmission (Martin, 2003). A diagram of the descending 
pain inhibitory pathway is illustrated in Figure 1.6. 
 
Figure 1.6. Descending pain inhibitory pathway. The descending 
systems (red) that modulate the transmission of ascending pain 
signals (blue). These modulatory systems originate in the somatic 
sensory cortex, the hypothalamus, the periaqueductal gray matter of 
the midbrain, the raphe nuclei, and other nuclei of the rostral ventral 
medulla. Adapted from Purves and Williams, 2001. 






3. Role of the brainstem in pain 
The brainstem is the most superior portion of the spinal cord that 
connects the diencephalon (hypothalamus and thalamus) with the spinal cord 
(Fishman et al., 2010). It is divided into three regions: the medulla oblongata, 
which forms the lowest part of the brainstem; the midbrain, which forms the 
uppermost part; and the pons, which lies between them (Okeson and Bell, 
2005). The brainstem is known to receive nociceptive information and control 
the descending spinal systems (Besson and Chaouch, 1987; Porro and Lui, 
2006). The nociceptive networks of the brainstem are involved in several 
functions, such as arousal, motor, and vegetative reactions (Bowsher, 1976; 
Villanueva et al., 1996; Benarroch, 2001; Porro and Lui, 2006). The trigeminal 
sensory brainstem nuclear complex (TBNC) is the major relay nucleus for 
sensory information from the craniofacial region (Dostrovsky, 2006). The 
TBNC consists of nuclei that were previously mentioned in section 2.1.3. 
These nuclei are involved in the transmission of nociceptive information to 
higher levels as well as descending modulation of nociceptive information 
(Dostrovsky, 2006). Other brainstem regions that play an important role in 
pain include the brainstem reticular formation and the PAG. 
 The brainstem reticular formation comprises the central core of the 
brainstem and contains a number of nuclei that can excite or inhibit incoming 
impulses, thus controls the overall activity in the brain (Martin, 2003; Okeson 
and Bell, 2005). Fibers passing through the reticular formation travel on to the 
thalamic nuclei. The level of activity of the reticular formation is determined to 
a great extent by the sensory signals that enter this area from the periphery. 






Pain signals, in particular, increase the activity in this area and strongly excite 
the brain to attention (Bowsher, 1976; Okeson and Bell, 2005). Activity of the 
reticular formation is influenced by many brainstem structures and incoming 
impulses. Certain areas of the reticular formation have concentrated cells that 
produce and release neurotransmitters, influencing the neural activity in the 
area – either enhancing or inhibiting the ascending input (Okeson and Bell, 
2005). Several nuclei are located in the reticular formation that regulate its 
function and ultimately brain activity; one such nucleus is the locus ceruleus, 
which contains high concentration of cells that produce norephinephrine, and 
is generally thought to excite brain activity (Okeson and Bell, 2005). Another 
area of the reticular formation is the nucleus raphe, which predominately 
produces serotonin and inhibits brain activity (Okeson and Bell, 2005). 
Substantia nigra is another area that produces high concentration of 
dopamine, and depending on the area, dopamine may inhibits or excites the 
brain activity (Okeson and Bell, 2005). The gigantocellular nucleus produces 
high levels of acetylcholine, which generally excite neural activity (Okeson 
and Bell, 2005). In addition, the reticular formation not only influence impulses 
to the thalamus and cortex, return impulses from these regions are also 
influenced. In other words, impulses leaving the cortex travel down to the 
thalamus and on through this facilitory area, activating this area and further 
facilitate descending impulses (Okeson and Bell, 2005). 
Besides the brainstem reticular formation, the PAG also plays an 
important role in pain, especially in the descending modulation of pain. As 
mentioned earlier, the PAG is a midbrain territory that surrounds the cerebral 






aqueduct and has a high concentration of neurotransmitter-producing neurons 
that can modulate nociceptive impulses (Okeson and Bell, 2005; Merker, 
2007). The PAG receives input from both ascending spinomesencephalic and 
descending pathways, the latter originating in the limbic forebrain, namely 
medial prefrontal cortex, rostral anterior cingulate cortex, amygdala, and 
hypothalamus (Fishman et al., 2010). Early systemic studies identified PAG 
and RVM as brainstem sites that elicit powerful surgical levels of analgesia 
through focal brain stimulation (Reynolds, 1969), subsequently more 
elaborated and referred to as “stimulus-induced analgesia” (Mayer et al., 
1971; Oliveras et al., 1975; Basbaum and Fields, 1978; Fishman et al., 2010). 
 
4. Role of the prefrontal cortex in pain 
 The prefrontal cortex is the anterior part of the frontal lobe and contains 
numerous neurons. It can be divided into different subdivisions: the mid-
dorsal, dorsolateral, ventrolateral, orbitofrontal, and medial frontal parts 
(Casey and Bushnell, 2000; Fishman et al., 2010). These frontal areas 
receive input from different sensory modalities and again project to different 
associative sensory areas, motor areas, and limbic structures (Fishman et al., 
2010).  With respect to pain, the PFC plays an important role in cognitive, 
attentional, and emotional processing of painful stimuli and recruitment of 
endogenous pain control (Fishman et al., 2010). A particular part of the PFC, 
the dorsolateral prefrontal cortex (DLPFC) is important for continuous 
monitoring of the external world, maintenance of information in short-term 
memory, and governing efficient performance control in the presence of 






distracting or conflicting stimuli (Bunge et al., 2001; Sakai et al., 2002; 
Fishman et al., 2010). In turn, orbital and medial portions of the prefrontal 
cortex are known to be important for mood and emotional behavior (Price et 
al., 1996; Fishman et al., 2010). 
Recent studies have indicated an important role of the prefrontal cortex 
during pain. Activation of the PFC is seen consistently in acute and chronic 
pain, and models of experimental pain (Ingvar, 1999; Peyron et al., 2000; 
Maihofner et al., 2004; Maihofner and Handwerker, 2005). Frontal lobe activity 
is associated with cognitive and attentional processing during noxious 
stimulation (Baron et al., 1999; Maihofner and Handwerker, 2005). Increased 
activity of the prefrontal cortex is associated with increased pain thresholds in 
animal models (Zhang et al., 1997), and decreased pain perception and 
intensity in human patients (Wiech et al., 2006; Bar et al., 2007). Functional 
neuroimaging and connectivity analyses suggest that increase in the activity 
of prefrontal cortex decreases pain perception via the descending pain 
inhibitory system (Valet et al., 2004; Xie et al., 2009). In addition, functional 
neuroimaging of the PFC shows increased activity during expectation of 
analgesia after administration of placebo, which implicates its involvement in 
the cognitive control of pain (Petrovic et al., 2002; Benedetti et al., 2005; 
Wager, 2005; Ramos, 2007).  
Indeed, there are studies that showed the role of prefrontal cortex in 
modulation of the descending inhibitory pain pathway via PAG. It was found 
that the PAG receives major inputs from the prefrontal cortex (An et al., 1998), 
which suggests the involvement of the prefrontal cortex in top-down 






modulation of descending pain inhibitory pathways. Evidence in support of 
this hypothesis comes from a fMRI study in which subjects were scanned 
during painful and non-painful heat stimulation while they were simultaneously 
doing either a cognitive distraction task or a neutral task (Valet et al., 2004). 
Distraction strongly abolished the pain-related activity in SII, posterior insula, 
thalamus, ACC, and posterior parietal cortex (Kupers, 2006). The reduced 
activity in the pain matrix was associated with increased activity in the medial 
frontal cortex, including perigenual ACC and orbitofrontal cortex. A functional 
connectivity analysis further revealed that during pain with distraction, there 
was an increased inter-regional covariation between activity in the 
cingulofrontal cortex and activity in the pulvinar and PAG, supporting a role of 
the prefrontal cortex in the top-down modulation of descending pain inhibitory 
pathways (Kupers, 2006). Thus, the above indicate an important role of the 
PFC in the modulation of pain. 
 
5. Role of immune cells in pain 
Noxious stimulus activate the pain system via peripheral terminals of 
primary sensory neurons that relays through spinal and supraspinal nuclei, 
and activate a matrix of cortical areas that is associated with the multiple 
conscious dimensions of pain (Marchand et al., 2005). This process involves 
the neuronal cells. However, the role of non-neuronal cells in the processing 
of pain-related information should not be ignored as cells of the immune 
system might strongly influence neuronal function in many persistent or 
chronic pain states (Marchand et al., 2005). 






Upon injury, inflammation is triggered by the innate immune activation 
of pattern-recognition receptors such as the Toll-like receptors (TLRs) that 
recognize and bind invading pathogens or endogenous molecules released 
from damaged cells (Guo and Schluesener, 2007; Takeuchi and Akira, 2010). 
TLRs are expressed in immune cells, including monocytes / macrophages 
and dendritic cells, and in immune-related cells such as keratinocytes. Binding 
to TLRs results in activation of nuclear factor-κB (NF-κB) signaling and the 
subsequent release of inflammatory cytokines (Ren and Dubner, 2010). 
Resident immune cells, mast cells and macrophages are also activated within 
minutes of injury, releasing proinflammatory cytokines, chemokines, effectors 
of the complement cascade (C3a and C5a) and vasodilators such as 
vasoactive amines and bradykinin. Blood-borne neutrophils, monocytes and T 
lymphocytes adhere to the vessel walls, extravasate and accumulate at the 
site of injury. These immune cells contribute to peripheral nociceptive 
sensitization by releasing soluble factors and interacting directly with 
nociceptors. In addition, several studies have indicated the important roles of 
immune cells in pain modulators not just in inflamed tissues, but also in 
damaged peripheral nerves and in the CNS (Marchand et al., 2005). 
 During inflammatory pain, different immune cell types will be recruited 
and contribute to abnormal pain sensitivity. One of the many immune cells 
includes the mast cells. Mast cells are granulated resident immune cells that 
are found close to capillaries in peripheral tissues. The mast cells contain a 
variety of inflammatory mediators. Some of these inflammatory mediators are 
stored in cytoplasmic granules, while others such as cytokines exist as 






precursors in the cell or attached to the cell surface, and are activated and 
released upon cleavage (Stassen et al., 2002; Marchand et al., 2005).  The 
mast cells also participate in innate host defense and allergic reactions and 
are degranulated within minutes of an inflammatory reaction, resulting in the 
release of histamine, bradykinin and other mediators that contribute to 
vasodilation (Lawrence et al., 2002). The involvement of mast cell in pain 
processing has been assessed in animal models of inflammation, and results 
have shown contribution of mast cells to pain in many experimental 
inflammatory pain states (Ribeiro et al., 2000; Parada et al., 2001; 
Drummond, 2004; Hoogerwerf et al., 2005). The role of mast cells in pain 
processing has also been implicated in clinical conditions of interstitial cystitis 
(Oberpenning et al., 2002) and chronic pancreatitis, where patients with pain 
show a 3.5-fold increase in the number of mast cells compared with patients 
without pain (Hoogerwerf et al., 2005). 
 Activated macrophages are another type of immune cells that are 
either resident or recruited from the blood by chemotactic cytokines and have 
been reported to contribute to experimental pain states (Marchand et al., 
2005). They are derived from circulating monocytes and are maintained by 
the local proliferation and maturation of blood monocytes after diapedesis 
(Ren and Dubner, 2010). Macrophages release many inflammatory 
mediators, mostly pro-inflammatory cytokines which includes tumour necrosis 
factor-α (TNF-α) and interleukin-1β (IL-1β), NGF, nitric oxide (NO) and 
prostanoids. Migrating blood monocytes are recruited to the site of injury and 
mature within hours to increase the proportion of macrophages in the inflamed 






area within days to weeks. Resident macrophages become phagocytic almost 
immediately after injury (Ren and Dubner, 2010). Macrophages have been 
shown to contribute significantly to the inflammatory pain upon recruitment to 
peripheral tissues, and contribute to nociceptor sensitization by releasing 
several soluble mediators (Ribeiro et al., 2000; Ren and Dubner, 2010). In 
addition, macrophage activation was shown to have a marked effect on the 
subsequent recruitment and activation of other cell types such as neutrophils 
to the site of inflammation (Souza et al., 1988). 
 Neutrophils are the most abundant polymorphonuclear leukocytes and 
are the earliest (within first hour of the onset of inflammation) inflammatory 
cell type to migrate through the vascular endothelium and accumulate at the 
site of injury, dominating the acute and early inflammatory responses 
(Marchand et al., 2005; Ren and Dubner, 2010).	    They produce several 
inflammatory factors, including lipoxygenase products, nitric oxide, cytokines 
and chemokines. In inflammatory conditions, they express opioids which 
might have an anti-nociceptive effects (Brack and Stein, 2004). The role of 
neutrophils has been studied by depleting them from the blood with cytotoxic 
agents or by increasing their numbers with granulocyte-colony stimulating 
factor (GCSF) (Marchand et al., 2005). Injection of GCSF into human skin was 
shown to induce pain (Heuft et al., 2004), and the prevention of neutrophil 
accumulation in inflammation induced by carrageenan reduces the associated 
inflammatory pain (Chou et al., 2003). The role of T and B cells in 
experimental pain models has been less studied. Likewise, these cells can 






produce inflammatory cytokines and chemokines, and contribute to innate 
immune responses (Marchand et al., 2005). 
Activity of glia was shown to increase in multiple pain processing 
pathways in response to peripheral injury (Raghavendra et al., 2004; Zhao et 
al., 2007; Wei et al., 2008). Activation signals are relayed to the brain by 
peripheral immune activation and through afferent nerve input (Guo et al., 
2007), circulating cytokines (Oka et al., 2007) and immune cell trafficking 
(Cao and DeLeo, 2008; Costigan et al., 2009). In addition, activation of spinal 
glia was observed in several animal models of inflammatory pain after 
injection of formalin (Sweitzer et al., 1999; Fu et al., 2000), zymosan (Sweitzer 
et al., 1999; Clark et al., 2007) or carrageenan (Hua et al., 2005; Eijkelkamp et 
al., 2010) into the hindpaw. 
Besides the pro-nociceptive effects of the immune cells, inhibitory 
effect of immune cells on pain was also observed. Upon injury, the immune 
system also releases factors that promote tissue recovery, suppress 
inflammation and reduce pain. Leukocytes and keratinocytes release opioids, 
mainly β-endorphin, after injury (Khodorova et al., 2003; Rittner et al., 2008). 
Recent studies indicate that endomorphins are expressed in T cells, 
macrophages and fibroblasts from the synovial tissue of patients with 
osteroarthritis and rheumatoid arthritis (Jessop et al., 2010). Inflammation 
caused the release of chemokines such as CXCL1 and CXCL2 that not only 
enhances leukocyte recruitment but also induces the release of opioid 
peptides from migrating leukocytes (Rittner et al., 2008). Activation of the 






endothelin-B receptor can also trigger the release of β-endorphin from 
keratinocytes (Khodorova et al., 2003). 
 In summary, it is recognized that there is a significant role of the 
immune system, microglia and astrocytes in the development of pain 
hypersensitivity (DeLeo et al., 2004; Scholz and Woolf, 2007; Ren and 
Dubner, 2008). Immune cells, glia and neurons form an integrated network in 
which activation of an immune response modulates the excitability of pain 
pathways (Ren and Dubner, 2010). Immune and immune-related cells, such 
as keratinocytes and vascular endothelial cells by tissue injury secrete anti-
inflammatory cytokines, pro-resolution lipid mediators and opioid peptides to 
suppress pain (Rittner et al., 2008; Hua and Cabot, 2010; Ren and Dubner, 
2010). In addition, microglia and astrocytes are immunocompetent cells that 
respond like immune cells within the CNS (Watkins and Maier, 1999). 
Activated microglia release mediators that act on neurons and nociceptors 
(Verge et al., 2004; Coull et al., 2005; Zhuang et al., 2007). Astrocytes are 
intimately associated with neurons and are in a unique position to regulate 
synaptic activity (Ren and Dubner, 2010). 
 
6. Animal models of orofacial pain 
 The use of questionnaires and scales, are reliable, accurate and 
versatile for the measurement of both experimental and clinical pain in human 
(Price et al., 1983; Mogil, 2009). Unlike human, non‑human animals cannot 
self‑report, but their behaviors in response to noxious stimuli can be reliably 
and objectively scored. However, the most reliable and commonly scored 






behaviors are simple reflexes (such as licking an inflamed paw), which seem 
to lack clinical face validity (Mogil, 2009). Nonetheless, the subjectivity of 
these measures has led to the search for surrogate biomarkers which to date 
have yet to be discovered. 
 Animal model of orofacial pain usually involve the injection of 
inflammatory agents or irritants such as formalin, complete Freundʼs adjuvant 
(CFA) and carrageenan into the temporomandibular joint or subcutaneous 
tissues of the face. The presence of pain is assessed by the behavior 
response (such as facial grooming) of the animal after applying noxious 
stimuli that produces transient pain to the face (Cahusac et al., 1990; Imbe et 
al., 2001; Yeo et al., 2004). Current pain evaluation methods include the hot-
plate and tail-flick tests (Le Bars et al., 2001) and the use of von Frey hair to 
assess mechanical allodynia (Vos et al., 1994; Tang et al., 2009). 
Subcutaneous injection of formalin into the facial whisker pad was shown to 
result in acute onset of facial rubbing in rats, and the duration of grooming 
activity and edema after formalin injection is concentration dependent 
(Clavelou et al., 1995). Injection of CFA into the rat perioral skin results in 
orofacial thermal hyperalgesia and mechanical allodynia (Imbe et al., 2001). 
Facial carrageenan injection in mice causes increased responses to facial 
stimulation with a von Frey hair 8 hr, 1 day, and 3 days after injection (Yeo et 
al., 2004). Besides injection of inflammatory agents into the facial region, 
transection or injury of the trigeminal nerve is also used as a model for 
neuropathic pain of the face and mouth. Transection of the inferior alveolar 
nerve, a branch of the trigeminal nerve, was demonstrated to produce 






mechanical allodynia in rats after 2 to 3 days (Tsuboi et al., 2004). Similarly, 
chronic constriction of infraorbital nerve was shown to result in nerve injury 
and mechanical hyperalgesia in rats (Vos et al., 1994). Although these animal 
models do not simulate every aspect of orofacial pain, they do, however, give 
insight into certain aspects of human pain conditions and lead to improved 
pain management for patients. 
 In the present study, the mouse model of orofacial pain involved the 
use of lambda carrageenan, which was injected subcutaneously into the facial 
region resulting in inflammatory pain. Carrageenan is a sulfated 
mucopolysaccharide derived from the Irish sea moss (Spillert et al., 1989), 
and is used to improve the texture of commercial food products. It has been 
suggested that carrageenan may be immunogenic due to its unusual alpha-
1,3-galactosidic link, which may provoke an immune response in the injected 
area leading to inflammation and pain. On the other hand, carrageenan was 
found to mediate the release of inflammatory mediators such as 
cyclooxygenase-2 and prostaglandin E2 resulting in inflammation (Nantel et 
al., 1999). 
 
7. Use of microarrays in pain research 
 Microarray is a powerful, high throughput technique that offers efficient 
means of genome-wide screening to correlate changes in transcript 
abundance with experimental treatment, or condition (Reilly et al., 2004). 
Microarrays have been successful in studying global gene expression in 
diseases such as cancer (Alizadeh et al., 2000), schizophrenia (Hakak et al., 






2001) and Alzheimer's disease (Blalock et al., 2004). Their application to 
diseases has significantly improved the discovery of genes whose expression 
correlates with the disease condition (Reilly et al., 2004). Microarrays have 
also been used in a variety of neuroscience (Parrish et al., 2004), and 
developmental studies (Arbeitman et al., 2002), as well as addressing 
questions in environmental and comparative physiology (Gracey and Cossins, 
2003; Kawano et al., 2003; Larkin et al., 2003). In pain research, microarrays 
have the potential to enhance our knowledge on the molecular basis of 
nociception and pain by simultaneously providing information on thousands of 
genes, thereby, opening up new avenues of investigation and possibly 
providing new gene targets for the alleviation of pain (Reilly et al., 2004). 
 In pain study, nociception can results in alteration of gene expression 
in different areas of the nervous system (Mogil and McCarson, 2000). 
Transcriptional regulation studies that investigated the expression levels of 
single genes have provided useful insights into the mechanisms that underlie 
nociceptive adaptation and also demonstrate the applicability of microarrays 
for gaining insights into nociceptive regulation (Reilly et al., 2004). Nociceptive 
processing involves a complex and integrative system with contributions from 
different levels of organization, thus, holistic approaches may yield 
penetrating insights into the mechanisms of pain (Reilly et al., 2004). 
Microarray analysis of transcript is an unbiased test, not based on the 
experimenter's preconceptions (Reilly et al., 2004). This approach provides 
information on several thousand genes and it is more likely that the complex 
molecular basis of pain is regulated by a number of genes rather than one 






candidate gene. Thus, microarrays give us unparalleled power to detect the 
involvement of multigene systems, which will fuel the more conventional 
hypothesis-driven research in future studies (Reilly et al., 2004). 
 
8. Aims of the Present Study 
 The brainstem and the prefrontal cortex are known to play important 
roles in pain, and they could be involved in different phases of pain 
processing - the brainstem seems to be more important in the immediate pain 
response, while higher order regions such as the prefrontal cortex seem to be 
more involved in the later response (Price, 2000; Petrovic et al., 2004). 
The brainstem is known to receive nociceptive information and is 
involved in the descending pain inhibitory system (Besson and Chaouch, 
1987; Porro and Lui, 2006). Of interest is the spinal trigeminal nucleus of the 
brainstem that plays an essential role in facial and dental pain, receiving 
information transmitting pain / temperature sensation from the face. The PFC 
on the other hand is important in the cognitive control of pain (Petrovic et al., 
2002; Benedetti et al., 2005; Wager, 2005; Ramos, 2007). Activation of the 
PFC is seen consistently in acute and chronic pain, and models of 
experimental pain (Ingvar, 1999; Peyron et al., 2000; Maihofner et al., 2004; 
Maihofner and Handwerker, 2005). This increased activity of PFC is 
associated with increased pain thresholds and decreased pain perception and 
intensity (Zhang et al., 1997; Wiech et al., 2006; Bar et al., 2007). To date, 
however, little is known about gene expression changes as well as microRNA 
(miRNA) changes in the brainstem and prefrontal cortex during pain. The 






present study was therefore carried out using microarray-based approaches 
to examine gene and miRNA expression changes in the brainstem and 
prefrontal cortex in a mouse facial carrageenan injection model of orofacial 
pain. 
The gene expression microarray data were analyzed and the 
differentially expressed genes between the control and treatment group were 
classified based on their gene ontology (GO). Genes that were involved in the 
gene ontology of interest were selected for validation using real-time RT-PCR, 
Western blot and immunohistochemistry. Possible role of these genes in the 
involvement of orofacial pain in the brainstem and PFC were elucidated and 
possible candidate for the treatment of pain were exploited. In addition, 
miRNA microarray data were also analyzed and the differentially expressed 
miRNAs were validated using real-time RT-PCR. The downstream targets of 















































Chapter 2.1 Gene Expression Analysis of the 





















Many of the studies examining gene regulation in pain conditions focus 
on the spinal cord. Currently, all published microarray studies in this area 
examine spinal cord and dorsal root ganglion (DRG) gene expression (Reilly 
et al., 2004). For example, microarray analysis of gene expression in the 
lumbar spinal cord, following the formalin test in the infant rat showed 
alteration of genes related to transcription factors, cell death and metal ion 
(Barr et al., 2005). cDNA microarray analysis of the rat spinal cord in 
neuropathic pain and electroacupuncture (EA) treatment models discovered 
an opioid receptor gene that demonstrated decreased expression in the 
neuropathic pain model and restored to the normal expression level after EA 
treatment (Ko et al., 2002). This study indicate the involvement of opioid 
signaling event in neuropathic pain and the analgesic effects of EA (Ko et al., 
2002). Microarray analysis of the DRG in rats following hind paw injection of 
carrageenan showed alteration in expression of genes related to cytokines in 
the inflamed tissue and DRG (Yang et al., 2007). The reasons for studies to 
focus on the spinal cord and DRG is because at spinal level, molecular 
adaptations play a large role in producing plasticity after injury (Hokfelt et al., 
1994), so global analysis of the spinal cord could result in novel 
understanding of associated physiological conditions (Reilly et al., 2004). 
 In the current study, pain was induced in the facial region (orofacial 
pain), which involves the trigeminal nucleus in the brainstem. To date, 
majority of microarray studies on pain were done in the spinal level, and little 
is known about the gene expression changes in the brainstem after pain. In 






view of the importance of the brainstem in orofacial pain, the present study 
was carried out using a microarray-based approach to examine global gene 
expression changes in the brainstem in a mouse facial carrageenan injection 
model of orofacial pain. 
 Alteration in the expression of several genes was observed in the 
ipsilateral mouse brainstem three days after facial carrageenan injection. P-
selectin and Icam-1 associated with leukocytes adhesion were selected for 
further analysis. Real-time RT-PCR was carried out to validate the microarray 
results i.e. P-selectin and Icam-1 at the gene level. In addition, Western blot 
analysis and immunohistochemistry were performed to validate the increased 
expression of P-selectin and ICAM-1 in the brainstem at the protein level. 
Using double immunofluorescence labeling, the expression of P-selectin and 
ICAM-1 were demonstrated to be on endothelial cells. The final experiment of 
this study involved the use of P-selectin inhibitor, which was found to be 
effective in reducing pain in several studies. Thus this inhibitor was used to 
inhibit the action of p-selectin and the results of the behavioral study 













2. Materials and methods 
2.1. Experimental animals 
Overall, 138 mice were used in the present series of experiments.  All 
were adult male C57BL/6J (B6) mice, 6-8 weeks of age and weighing 
approximately 20-30 g. These animals were supplied by the Laboratory 
Animals Centre, Singapore. All mice were labelled with a coded number tag 
on their tails, to allow the behavioral responses of an individual mouse to be 
followed at different time intervals.   
 Mice were randomly divided into four groups, (a) right and (b) left facial 
carrageenan application, and (c,d) the respective untreated controls. Mice 
were assessed for responses to von Frey hair stimulation of the face before 
injections, and from day 1 to day 12 after injections. All procedures were in 
accordance with guidelines and regulations of the Committee for Research 
and Ethical Issues of IASP and were approved by the Institutional Animal 
Care and Use Committee of NUS. 
 
2.2. Facial carrageenan injection 
Treated mice received facial injection of 50 µl carrageenan (2 mg / 50 
µl saline of lambda carrageenan, Sigma-Aldrich, St. Louis, MO, USA) in the 
subcutaneous tissue over the right / left maxillary, ophthalmic and mandibular 
region, while still under anaesthesia (75 mg/kg of ketamine + 1 mg/kg of 
medetomidine). The injection of carrageenan produced a constant swelling of 
approximately 4 mm in diameter, and is established to cause allodynia in the 
injected area in the days following the injection (Ng and Ong, 2001). Control 






mice were given anaesthesia but did not receive facial carrageenan injection. 
All procedures involving the mice were in accordance with guidelines of the 
Committee for Research and Ethical Issues of IASP and were approved by 
the Institutional Animal Care and Use Committee of NUS. 
 
2.3. Assessment of responses to mechanical stimulations 
 Eight mice per group were used for behavioral assessments and the 
assessments were carried out in a blinded manner as previously described 
(Vos et al., 1994). Mice were tested individually in a deep rectangular 
stainless steel tank, sized (L x W x H) 60 × 40 × 25 cm. The experimenter 
reached into the tank with a von Frey hair to habituate the mice to the 
reaching movements for 5 -10 min before testing. Mice were observed during 
this time, to ensure that they were able to move freely. Test stimuli were 
administered when the mice were neither moving nor freezing  and with all 
four paws placed on the ground while exhibiting sniffing behavior. A new 
stimulus was applied at least 30 seconds after the previous stimulation 
Directed facial grooming, i.e. uninterrupted series of face-wash strokes 
directed to the stimulated facial area, was used as an indicator of unilateral 
facial pain in freely moving mice. The carrageenan-injected area of the face 
was probed 20 times with a von Frey hair (Touch-Test Sensory Evaluator, 
North Coast Medical, Morgan Hill, USA) to obtain sufficient number of 
responses to reduce variability among individual animals in each group. A 
filament delivering 1.4 g force (4.17 log units = 13.725 mN) was used. The 
number of immediate asymmetric face grooming / scratching strokes were 






summed to compute the total number of face strokes exhibited by an animal 
after 20 stimulations. Mean and standard errors of the total responses were 
then calculated for each experimental group, and possible significant 
differences between the means were examined using one-way ANOVA with 
Bonferroni multiple comparison test. P < 0.05 was considered significant. 
 
2.4. Microarray data collection and analysis 
A total of 16 independent samples were used, and none were pooled. 
The samples were divided into four treatment groups (four mice per group) – 
four for the left half of the brainstem of mice receiving left-sided facial 
carrageenan injection, four for the left half of brainstem of untreated controls, 
and similarly for the right half of the brainstem of mice receiving right-sided 
facial carrageenan injection and its corresponding controls. Mice were deeply 
anaesthetized with intraperitoneal injection of 75 mg/kg of ketamine + 1 mg/kg 
of medetomidine, and decapitated. Brains were removed and the left and right 
halves of brainstems dissected out, and stored at -80 °C freezer until analysis. 
The area of the brainstem dissected out is delimited by the vertical lines 
(Figure 3.1). Gene expression profiles of the tissues were established using 
Affymetrix Mouse Genome 430 2.0 microarrays (Affymetrix, CA, USA). Total 
RNA was isolated using TRIzol reagent (Invitrogen, CA, USA) according to 
the manufacturer's protocol, and RNeasy® Mini Kit (Qiagen, Inc., CA, USA) 
was used to purify the RNA. The RNA was then submitted to the BFIG Core 
facility Lab at NUS, where RNA quality was determined using the Agilent 2100 
Bioanalyzer, and cRNA generated and labelled by the one-cycle target 






labelling method. cRNA generated from each sample was hybridized to a 
single array according to standard Affymetrix protocols. 
 
 
Figure 3.1. Lateral view of a mouse brain. The extent of the spinal 
trigeminal nucleus is delimited by the vertical lines. 
 
A total of 16 independent samples were hybridized and initial image 
analysis of the microarray chips was performed with Affymetrix GCOS 1.2 
software. Data were subsequently exported into GeneSpring v7.3 (Agilent 
Technologies, CA, USA) software for further analysis using parametric tests 
based on the cross gene error model (PCGEM). Unpaired t-tests were used to 
identify differentially expressed genes between experimental and control 
animals. Finally, differentially expressed genes were then classified based on 
their known biological functions using Database for Annotation, Visualization, 
and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/) (Dennis et 










2.5. Real-time RT-PCR 
The same RNA extracted for the microarray analysis (n = 16) together 
with a new batch of samples (n = 16) were used for the validation of 
microarray results. Samples were reverse transcribed using High-Capacity 
cDNA Reverse Transcription Kits (Applied Biosystems, CA, USA). Reaction 
conditions were 25 oC for 10 min, 37 oC for 120 min and 85 oC for 5 min. Real-
time PCR amplification was then carried out in the 7500 Real-time PCR 
system (Applied Biosystems, CA, USA) using TaqMan® Universal PCR 
Master Mix (Applied Biosystems, CA, USA) and gene-specific primers and 
probes, P-selectin (Mm00441295_m1, Applied Biosystems, CA, USA) and 
Icam1 (Mm00516023_m1, Applied Biosystems, CA, USA) according to 
manufacturerʼs protocols. β-actin was used as internal control, and all primers 
and probes were synthesized by Applied Biosystems. The PCR conditions 
were: an initial incubation of 50 oC for 2 min and 95 oC for 10 min followed by 
40 cycles of 95 oC for 15 s and 60 oC for 1 min. All reactions were carried out 
in triplicate. The threshold cycle, CT, which correlates inversely with the levels 
of target mRNA, was measured as the number of cycles at which the reporter 
fluorescence emission exceeds the preset threshold level. The amplified 
transcripts were quantified using the comparative CT method as described 
previously (Livak and Schmittgen, 2001), with the formula for relative fold 
change = 2–∆∆CT. The mean was calculated and possible significant 
differences analyzed using Studentʼs t-tests. P < 0.05 was considered 
significant. 
 






2.6. Western blot analysis 
A further six mice were used for this portion of the work. Three mice 
were injected with carrageenan on the right side of the face and sacrificed 3 
days after injection. The remaining three mice were used as controls. They 
were deeply anesthetized and decapitated, the right half of brainstem was 
removed and homogenized in T-PER® Tissue Protein Extraction consisting of 
1% EDTA solution and 1% HaltTM protease inhibitor (Thermo Fisher Scientific, 
Rockford, IL, USA). After centrifugation at 10,000 g for 10 min at 4oC, the 
supernatant was collected. The protein concentrations in the preparation were 
then measured using the Bio-Rad protein assay kit. Prior to resolving the 
sample, the proteins were denatured by heating the sample in the presence of 
SDS and a reducing agent (DTT) for 10 mins at 95-100 oC. Protein standards 
containing molecular weight of 250, 150, 100, 75, 50, 37, 25, 20, 15 and 10 
kDa were used (Precision Plus Protein Dual Color Standards, Bio-Rad 
Laboratories, CA, USA). The homogenates (40 μg) were resolved in 10% 
SDS-polyacrylamide gels under reducing conditions and electrotransferred to 
a polyvinylidene difluoride (PVDF) membrane. Non-specific binding sites on 
the PVDF membrane were blocked by incubating with 5% non-fat milk in tris-
buffered saline (TBS) containing 0.1% Tween-20 (TBST)  for 1 hr. The PVDF 
membrane was then incubated overnight in goat polyclonal antibodies to P-
selectin (sc-6941, Santa Cruz Biotechnology, CA, USA; diluted 1:200) and 
Intercellular adhesion molecule 1 (ICAM-1) (sc-1511, Santa Cruz 
Biotechnology, CA, USA; diluted 1:200), in 1% bovine serum albumin in 
TBST. Negative controls were carried out using facial carrageenan-injected 






mice incubated with P-selectin (sc-6943 P, Santa Cruz Biotechnology, CA, 
USA) or ICAM-1 (sc-1511 P, Santa Cruz Biotechnology, CA, USA) antigen-
absorbed antibodies. After washing with TBST, the membrane was incubated 
with horseradish peroxidase-conjugated anti-goat IgG (Thermo Fisher 
Scientific, Rockford, IL, USA; diluted 1:1,000 in TBST) for 1 hr at room 
temperature. Immunoreactivity was visualized using a chemiluminescence 
substrate (Supersignal West Pico, Thermo Fisher Scientific, Rockford, IL, 
USA). Loading controls were carried out by incubating the blots at room 
temperature for 10 min with stripping buffer (Restore Western Blot Stripping 
Buffer, Thermo Fisher Scientific, Rockford, IL, USA), followed by reprobing 
with a mouse monoclonal antibody to β-actin (Sigma-Aldrich, St. Louis, MO, 
USA; diluted 1:10,000 in TBST) and horseradish peroxidase-conjugated anti-
mouse IgG ( Thermo Fisher Scientific, Rockford, IL, USA; diiluteed 1:10,000 in 
TBST). Exposed films containing blots were scanned and the densities of the 
bands measured, using Gel-Pro Analyzer 3.1 program (Media Cybernetics, 
Silver Spring, MD, USA). The densities of the P-selectin and ICAM-1 bands 
were normalized against those of β-actin, and the mean ratios calculated. 
Possible significant differences between the values from the facial 
carrageenan-injected mice and control mice were then analysed, using 
Student's t-tests. P < 0.05 was considered significant. 
 
2.7. Immunohistochemistry 
 Eight adult male mice were used for this portion of the study. Four mice 
were injected with carrageenan on the right side of the face, and four were 






used as untreated controls. The mice were sacrificed after 3 days by deep 
anaesthesia and perfusion through the left cardiac ventricle with a solution of 
4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were 
dissected out, and blocks containing the brainstem were sectioned at 40 µm 
using a freezing microtome. The sections were then washed three times in 
phosphate-buffered saline (PBS) containing 0.1% Triton (PBS-Tx) to remove 
traces of fixative, and immersed for 1 hr in a solution of 5% normal rabbit 
serum and 1% bovine serum albumin in PBS-Tx to block non-specific binding 
of antibodies. They were then incubated overnight with goat polyclonal 
antibodies to P-selectin (sc-6943, Santa Cruz Biotechnology, CA, USA; 
diluted 1:100) and ICAM-1 (sc-1511, Santa Cruz Biotechnology, CA, USA; 
diluted 1:100). Negative controls were carried out by incubation with P-
selectin (sc-6943 P, Santa Cruz Biotechnology, CA, USA) or ICAM-1 (sc-1511 
P, Santa Cruz Biotechnology, CA, USA) antigen-absorbed antibodies. The 
sections were then washed three times in PBS, and incubated for 1 hr at room 
temperature in 1:200 dilution of biotinylated rabbit anti-goat IgG (Vector 
Laboratories, Burlingame, USA). This was followed by three changes of PBS 
to remove unreacted secondary antibody. The sections were then reacted for 
1 hr at room temperature with an avidin-biotinylated horseradish peroxidase 
complex. The reaction was visualized by treatment for 5 min in 0.05% 3.3-
diaminobenzidine tetrahydrochloride (DAB) solution in Tris-buffered saline 
containing 0.05% hydrogen peroxide. The color reaction was stopped with 
several washes of Tris buffer. Sections were counterstained with methyl green 
before coverslipping. Light micrographs were captured using Olympus BX51 






system microscope (Olympus Corporation, Tokyo, Japan). The location of the 
spinal trigeminal nucleus examined is shown in Figure 3.2. 
 
 
Figure 3.2. Diagram of a mouse brainstem. The spinal trigeminal nucleus 
is demarcated by the dotted line. The square box indicates the 
approximate region where images in Figure 3.7 and 3.8 were obtained. 
 
2.8. Double immunofluorescence labeling 
Four adult male mice were used for this portion of the study. The mice 
were injected with carrageenan on the right side of the face and sacrificed 
after 3 days by deep anaesthesia and perfusion through the left cardiac 
ventricle with a solution of 4% paraformaldehyde in 0.1 M phosphate buffer 
(pH 7.4). The brains were dissected out, embedded in an embedding matrix 
and blocks containing the brainstem were sectioned at 20 µm using a freezing 
microtome. The sections were processed for double immunofluorescence 
staining. They were washed three times in PBS and incubated in a blocking 
solution composed of 5% donkey serum (Vector) and 0.1% Triton X-100 for 1 
hr, followed by incubation with goat polyclonal antibodies to P-selectin (sc-
6943, Santa Cruz Biotechnology, CA, USA; diluted 1:100) and ICAM-1 (sc-






1511, Santa Cruz Biotechnology, CA, USA; diluted 1:100) and rabbit 
polyclonal antibody to Von Willebrand factor (vWF) (AB7356, Millipore, CA, 
USA, diluted 1:200), a marker for endothelial cells, overnight. The sections 
were then washed three times in PBS, and incubated for 1 hr at room 
temperature in 1:200 dilution of FITC-conjugated donkey anti-goat IgG, and 
Cy3-conjugated donkey anti-rabbit IgG (both from Millipore, USA, CA). The 
sections were mounted and examined using an Olympus FluoView FV1000 
confocal microscopy. The region examined is shown in Figure 3.2. 
 
2.9. Effect of P-selectin inhibitor treatment on behavioral responses in 
facial carrageenan-injected mice 
 Seven groups of mice were used in this portion of the study and the 
groups are summarized in Table 3.1. The first five groups (8 mice per group) 
received right facial carrageenan injection and daily intraperitoneal injection of 
10 mg/kg, 1 mg/kg, 0.1 mg/kg, 0.01 mg/kg or 0.001 mg/kg of P-selectin 
inhibitor, KF38789 (Tocris Cookson, MO, USA) (dissolved in 1% DMSO) for 
12 days. This inhibitor has previously been shown to inhibit P-selectin-
dependent cell adhesion and leukocyte recruitment in mouse peritonitis when 
injected intravenously (Ohta et al., 2001). The sixth group (8 mice) received 
right facial carrageenan injection and daily intraperitoneal injection of 1% 
DMSO (vehicle control) for 12 days. The last group (8 mice) did not receive 
facial carrageenan injection, but received daily intraperitoneal injection of 10 
mg/kg of KF38789 in 1% DMSO for 12 days. Responses to von Frey hair 
stimulation were quantified daily in a blinded manner as described earlier. 






Mean and standard errors of the total responses were then calculated for 
each experimental group, and possible significant differences between the 
means were examined using one-way ANOVA with Bonferroni multiple 
comparison test. P < 0.05 was considered significant. 
 
















P-selectin inhibitor, KF38789 1% DMSO 10 mg/kg 8 
P-selectin inhibitor, KF38789 1% DMSO 1 mg/kg 8 
P-selectin inhibitor, KF38789 1% DMSO 0.1 mg/kg 8 
P-selectin inhibitor, KF38789 1% DMSO 0.01 mg/kg 8 
P-selectin inhibitor, KF38789 1% DMSO 0.001 mg/kg 8 





















P-selectin inhibitor, KF38789 1% DMSO 10 mg/kg  8 
Table 3.1. Treatment groups for the study of P-selectin inhibitor, KF38789 on the behavioral 
















3.1. Behavioral responses to pain after facial carrageenan injection 
 Study on behavioral responses to orofacial pain showed an increase in 
the number of face strokes after either left or right-sided facial carrageenan 
injection with peak nociceptive responses on the 3rd and 4th day. Thereafter 
the number of face strokes declined, to near baseline on the 10th-12th day 
(Figure 3.3). The third day after facial carrageenan injection was thus selected 
for analysis, corresponding to the peak time of mechanical allodynia. 
 
 
Figure 3.3. Responses to von Frey hair stimulation of the face after 
facial carrageenan injection. (A) Left-sided and (B) right-sided facial 
carrageenan injection. The Y-axis represents number of responses to 
von Frey hair stimulation of the carrageenan-injected areas of the face. 
BI: before injection, 1D to 12D refer to 1 day to 12 days after injection. 
Control: untreated control. Carrageenan: after facial carrageenan 
injection. Analyzed by Studentʼs t-test.. Asterisks indicate significant 
difference at p-value of <0.05 (*), <0.01 (**), and <0.001 (***). 






3.2. Microarray analysis 
 Facial carrageenan-injected mice showed increasing behavioral 
responses to stimulation with the von Frey hair up to the third day after 
carrageenan injection, with significantly increased responses compared to 
control mice at post-injection days 1, 2 and 3 (Figure 3.4). They were 
sacrificed on the third day after facial carrageenan injection (time of 
approximate peak nociceptive response), and the brainstems were harvested 
for microarray analysis. 
 
Figure 3.4. Responses to von Frey hair stimulation of the face after facial carrageenan 
injection. (A) Left-sided facial carrageenan injection. (B) Right-sided facial carrageenan 
injection. The Y-axis represents number of responses to von Frey hair stimulation of the 
carrageenan injected areas of the face. BI: before injection, 1D, 2D, 3D refer to 1 day, 2 days, 
and 3 days after injection. Control: untreated control. Carrageenan: after facial carrageenan 
injection. Analyzed by Studentʼs t-test. Asterisks indicate significant difference at p-value of 
<0.05 (*), <0.01 (**), and <0.001 (***). 
 
Gene expression profile of the left half of the brainstem in mice that 
received left facial carrageenan injection was compared to the left half of the 
brainstem of untreated controls. A total of 646 genes were altered, with fold 
change of more than 2-fold. Of these, genes with uncertain ontology were 
ignored, leaving 161 known genes that had more than 2-fold change.  
Likewise, gene expression profile of the right half of the brainstem in mice that 
received right facial carrageenan injection was compared to the right half of 
the brainstem of untreated controls. A total of 539 genes were altered, that 






had greater than 2-fold change. Of these, genes with uncertain ontology were 
ignored, leaving 173 known genes that had more than 2-fold change. 
Common genes between the differentially expressed genes in the left half of 
brainstem (161 genes) and the right half of brainstem (173 genes) were 
identified. This step was carried out to minimize the impact of false positives 
and to disregard possible side specific changes in this study. The result is a 
relatively small list of 22 genes (Table 3.2).  
 









(Mean ± SD) 
P-value 
Lipocalin 2 Lcn2  17.4 ± 7.8 0.0022 3.5 ± 2.8 0.017 
Prostaglandin-endoperoxide 
synthase 2 Ptgs2  13.7 ± 6.9 0.0018 6.7 ± 2.7 0.0073 
Cholesterol 25-hydroxylase Ch25h  13.2 ± 5.8 0.00076 6.2 ± 2.0 0.02 
Selectin, platelet* Selp  12.3 ± 7.2 0.0019 2.6 ± 1.4 0.047 
Chemokine (C-C motif) ligand 12 Ccl12  8.9 ± 2.5 0.00010 14.2 ± 7.1 0.0059 
Angiogenin 4 Ang 4  5.1 ± 0.9 0.014 3.8 ± 0.9 0.019 
Intercellular adhesion molecule* Icam1  4.5 ± 1.4 0.00033 2.8 ± 1.3 0.013 
Von Willebrand factor homolog Vwf  4.8 ± 1.6 0.00021 2.3 ± 0.6 0.0018 
Suppressor of cytokine signaling 3 Socs3  3.8 ± 2.6 0.049 2.1 ± 0.5 0.0013 
Homeo box, msh-like 2 Msx2  2.9 ± 0.6 0.022 2.2 ± 0.7 0.035 
Eyes absent 3 homolog Eya3  2.5 ± 1.0 0.05 2.7 ± 0.9 0.047 
Solute carrier family 25, member 19 Slc25a19  2.4 ± 0.6 0.0016 3.5 ± 0.8 0.022 
Cathelicidin antimicrobial peptide Camp -4.3 ± 0.4 0.045 -2.8 ± 0.6 0.022 
Vacuolar protein sorting 29 Vps29 -3.4 ± 0.6 0.014 -3.1 ± 0.5 0.049 
Fatty acid binding protein 7, brain Fabp7 -3.2 ± 0.1 0.0039 -2.2 ± 0.04 0.00027 
Transthyretin Ttr -2.9 ± 0.6 0.034 -2.4 ± 0.4 0.042 
Aquaporin 7 Aqp7 -2.9 ± 1.4 0.043 -2.0 ± 0.2 0.032 
Bone morphogenetic protein 15 Bmp15 -2.9 ± 0.5 0.028 -4.3 ± 0.6 0.027 
Cadherin 3 Cdh3 -2.7 ± 1.4 0.029 -3.7 ± 0.2 0.016 
Sclerostin domain containing 1 Sostdc1 -2.5 ± 0.5 0.017 -2.8 ± 0.7 0.019 
Myosin, heavy polypeptide 1, 
skeletal muscle Myh1 -2.3 ± 0.6 0.037 -8.0 ± 0.2 0.048 
Heat shock protein 1A Hspa1a -2.1 ± 0.3 0.045 -2.3 ± 0.2 0.018 
Table 3.2. Differentially expressed genes in the ipsilateral brainstem after facial carrageenan 
injection. These are common genes that show upregulation or downregulation by more than two-
fold, after right or left-sided facial carrageenan injection, compared to brainstem of the respective 
controls. Bold indicate genes analyzed by real-time RT-PCR. Asterisks indicate genes validated 
by real-time RT-PCR. 






These genes were categorized using the GO term enrichment analysis 
from the DAVID resource website, and sorted based on their Fisher Exact p-
value (Dennis et al., 2003; Huang da et al., 2009). The Fisher Exact test is 
used to determine whether the proportions of those falling into each category 
differs by group, and in DAVID annotation system, Fisher Exact is adopted to 
measure the gene-enrichment in annotation terms. A p-value of equal or 
smaller than 0.05 is considered strongly enriched in the annotation categories. 
The category with the lowest Fisher Exact p-value (2 of the 22 genes) was 
annotated with the GO term ʻʻleukocyte adhesion” (Fisher Exact p-value = 
1.9E-2) and was selected for analysis. The two genes involved in this 
ontology were Selp and Icam-1, and were selected for subsequent validation 
and analysis. Other GO terms of the 22 genes are presented in Table 3.3.  
 
GO-Term Gene counts Fisher Exact p-value 
Leukocyte adhesion 2 1.9E-02 
Defense response 4 2.1E-02 
Negative regulation of biological process 6 2.7E-02 
Cell adhesion 4 3.7E-02 
Biological adhesion 4 3.7E-02 
Cell-cell adhesion 3 3.9E-02 
Response to other organism 3 3.9E-02 
Organ development 6 6.2E-02 
Response to biotic stimulus 3 6.5E-02 
Negative regulation of cellular process 5 6.9E-02 
Regulation of response to stimulus 3 7.1E-02 
Multi-organism process 3 8.2E-02 
Negative regulation of response to stimulus 2 8.3E-02 
Immune system process 4 8.6E-02 
Table 3.3. Gene Ontology (GO) terms of the 22 common genes. These genes were 
categorized using the GO-term enrichment analysis from the DAVID resource website, and 
sorted based on their Fisher Exact p-value. A p-value of equal or smaller than 0.05 is 
considered strongly enriched in the annotation categories. 






3.3. Validation of differentially expressed genes by real-time RT-PCR 
 The results obtained from the microarray data analysis revealed the 
altered transcriptions of many genes after facial carrageenan injection. To 
validate the microarray data, the transcription levels in some of the 
microarray-identified genes were further determined using real-time RT-
PCR. The genes that were chosen for validation by real-time RT-PCR were 
leukocyte adhesion-related genes, which include Selp and Icam-1. The 
relative fold changes of Selp and Icam-1 for the left half of brainstem were 
10.8 and 5.9, respectively (Figure 3.5A), while the relative fold changes of 
Selp and Icam-1 for the right half of brainstem were 25.3 and 3.0, 
respectively (Figure 3.5B). Both of the genes showed similar transcription 
alteration patterns between the real-time RT-PCR and the microarray 
assays, which further confirmed the consistency of the results, indicating a 
high reliability of the microarray data obtained in this study. 
 
 
Figure 3.5. Real-time RT-PCR analysis of differentially expressed genes in the ipsilateral 
brainstem after facial carrageenan injection. P-selectin and Icam-1 genes in the mouse 
brainstem after facial carrageenan injection. (A) Left-sided facial carrageenan injection. B: 
Right-sided facial carrageenan injection. Control: untreated control. Carrageenan: after facial 
carrageenan injection. Analyzed by Studentʼs t-test. Asterisks indicate significant difference at 
p-value of <0.05 (*), <0.01 (**), and <0.001 (***). 
 






3.4. Western blot analysis of P-selectin and ICAM-1 
 Western blot analysis of extracts from the right half of brainstem of right 
facial carrageenan-injected mice detected bands of P-selectin and ICAM-1 at 
around 140 kDa and 90kDa, respectively, consistent with the expected 
molecular weights of these proteins (Walter et al., 1997; Yang et al., 1999). 
No band was detected in the negative control, incubated with P-selectin or 
ICAM-1 antigen-absorbed antibodies. Significant increase in the density ratios 
of P-selectin and ICAM-1 to β-actin bands was observed in Western blots of 3 
days post carrageenan-injected mice, compared to the control mice (6.8 and 




Figure 3.6. Western blot analysis of (A) P-selectin and (B) ICAM-1 in homogenates of 
brainstem from 3 days post facial carrageenan-injected mice and control mice. (C and D) 
Both P-selectin and ICAM-1 are increased in facial carrageenan injected mice as 
determined by band intensity quantification normalized to β-actin, and analyzed by 
Studentʼs t-test. Asterisks indicate significant difference at p-value of <0.05 (*), <0.01 (**), 
and <0.001 (***). 






3.5. Immunohistochemistry of P-selectin and ICAM-1 
 Light staining to P-selectin and ICAM-1 was observed in the brainstem 
of control mice (Figure 3.7A and B, respectively). Sections incubated with 
antigen-absorbed antibody showed absence of labeling, indicating specificity 
of the P-selectin and ICAM-1 antibodies (Figure 3.7C and D, respectively). 
Light staining to P-selectin and ICAM-1 was observed in the brainstem of left 
spinal trigeminal nucleus of right facial carrageenan-injected mice (Figure 
3.7E and F, respectively). In contrast, mice that received right facial 
carrageenan injection showed significantly increased density of P-selectin and 
ICAM-1 staining in the right spinal trigeminal nucleus, 3 days after facial 
carrageenan injection (Figure 3.7G and H, respectively). Staining of P-selectin 
and ICAM-1 was observed in the endothelial cells of blood vessels in higher 
magnification in the right spinal trigeminal nucleus after right facial 
carrageenan injection (Figure 3.7I and J). Nuclei of cells are labeled green 
















Figure 3.7. Light micrographs of the spinal trigeminal nucleus. Left and right 
column: sections incubated with P-selectin and ICAM-1 antibodies, respectively. 
R and L refer to the right (side of facial carrageenan injection) and left 
(uninjected side) halves of brainstem, respectively. (A and B) Light staining to P-
selectin and ICAM-1 was observed in the spinal trigeminal nucleus of control 
mice. (C and D) Section incubated with P-selectin and ICAM-1 antigen-
absorbed antibodies. (E and F) Light staining to P-selectin and ICAM-1 was 
observed in the left spinal trigeminal nucleus of right facial carrageenan-injected 
mice (G-J) Mice that received right facial carrageenan injection showed 
increased staining of P-selectin and ICAM-1 in vessels of the right spinal 
trigeminal nucleus (arrows). Scale: A-H = 60 µm, I and J = 50 µm. 






3.6. Localization of P-selectin and ICAM-1 
 P-selectin and ICAM-1 staining were observed in the trigeminal 
nucleus of brainstem with an endothelial pattern (Figure 3.8A and D, 
respectively). Double staining for P-selectin and ICAM-1 with vWF, an 
endothelial marker was performed in the brainstem of 3 days post 
carrageenan-injected mice. vWF stained the endothelium of blood vessels 
(Figure 3.8B and E). Upon merging of P-selectin and ICAM-1 with vWF, the 
endothelial localization of P-selectin and ICAM-1 could be clearly shown by 
double staining with vWF (Figure 3.8C and F). Taken together these 
immunohistological data show co-localization of P-selectin and ICAM-1 with 
vWF, indicating expression of these proteins on endothelial cells of blood 
vessels in the spinal trigeminal nucleus of the brainstem. 
 
 
Figure 3.8. Double immunofluorescence labeling with antibodies against P-selectin or ICAM-1 
and vWF in the trigeminal nucleus of 3 days post carrageenan-injected mice. (A–C) P-selectin 
immunopositive cells (A, green) were double labeled with vWF, an endothelial marker (B, 
red). The red–green overlay of the antigens shows the expression of P-selectin on endothelial 
cells (C, arrows). (D–F) ICAM-1 immunopositive cells (D, green) were double labeled with 
vWF (E, red). The red–green overlay of the antigens shows the expression of ICAM-1 on 
endothelial cells (F, arrows). Scale: A-F = 10 µm. 
 






3.7. Effect of P-selectin inhibitor, KF38789 on nociceptive responses of 
carrageenan-injected mice 
 Mice that received daily P-selectin inhibitor, KF38789 without facial 
carrageenan injection, showed no baseline withdrawal responsiveness 
throughout the experiment. Carrageenan-injected mice that received daily 
intraperitoneal injection of 10 mg/kg, 1 mg/kg or 0.1 mg/kg of KF38789, 
showed comparable responses to carrageenan-injected mice that received 
daily intraperitoneal injection of 1% DMSO (vehicle), on the 1st and 2nd day 
after facial carrageenan injection. Thereafter, the number of responses began 
to diverge, and mice that received 10 mg/kg, 1 mg/kg and 0.1 mg/kg of 
KF38789 showed fewer responses compared to those injected with vehicle. 
The differences between KF38789 treated mice and vehicle treated mice were 
significant from the 3rd to 9th days after facial carrageenan injection. On the 
other hand, carrageenan-injected mice that received two lower doses, i.e. 
0.01 mg/kg and 0.001 mg/kg of KF38789, showed no difference from 
carrageenan-injected mice that received daily intraperitoneal injection of 
vehicle at all times, thus KF38789 was ineffective in modulating mechanical 














Figure 3.9. Responses to von Frey hair stimulation of the face after tissue inflammation 
induced by facial carrageenan injection after daily intraperitoneal injection of P-selectin 
inhibitor, KF38789. The Y-axis represents number of responses to von Frey hair stimulation 
of the carrageenan-injected areas of the face. BI: before injection, 1D to 12D refer to 1 day to 
12 days after injection. Control + KF38789 (10 mg/kg): control and 10 mg/kg of KF38789 
injection. Carrageenan + 1% DMSO (vehicle): facial carrageenan injection and intraperitoneal 
vehicle injection. Carrageenan + KF38789 (0.001 mg/kg): facial carrageenan injection and 
0.001 mg/kg of KF38789 injection. Carrageenan + KF38789 (0.01 mg/kg): facial carrageenan 
injection and 0.01 mg/kg of KF38789 injection. Carrageenan + KF38789 (0.1 mg/kg): facial 
carrageenan injection and 0.1 mg/kg of KF38789 injection. Carrageenan + KF38789 (1 
mg/kg): facial carrageenan injection and 1 mg/kg of KF38789 injection. Carrageenan + 
KF38789 (10 mg/kg): facial carrageenan injection and 10 mg/kg of KF38789 injection. Mice 
treated with Carrageenan + KF38789 (10 mg/kg), Carrageenan + KF38789 (1 mg/kg) and 
Carrageenan + KF38789 (0.1 mg/kg) showed statistically significant difference against mice 
treated with Carrageenan + 1% DMSO (vehicle), from the 3rd to 9th days after carrageenan 
injection (P < 0.05). However, mice treated with Carrageenan + KF38789 (0.01 mg/kg) and 
Carrageenan + KF38789 (0.001 mg/kg) showed no statistical difference from mice treated 
with Carrageenan + 1% DMSO (vehicle) at all times. Analyzed by one-way ANOVA with 















The present study aimed at examining gene expression changes in the 
brainstem during inflammatory pain. Gene expression analysis was examined 
in both the left and right halves of the brainstem and the common genes 
between both halves of the brainstem were identified for analysis. This was 
carried out to minimize the impact of false positives and to disregard possible 
side specific changes such that the observed gene expression changes can 
be attribute/applied to either sides of the brainstem. Analysis of the microarray 
data revealed “leukocyte adhesion” as the most dominant ontology term 
based upon the lowest Fisher Exact p-value. The increased expression of P-
selectin and Icam-1 was verified by real-time RT-PCR and Western blot 
analysis in the ipsilateral brainstem after facial carrageenan injection to either 
side. Immunohistochemistry showed greater staining on endothelial cells on 
the side of the injection, compared to the controls. Colocalization of P-selectin 
and ICAM-1 with vWF using double immunofluorescence labeling confirmed 
the localization of P-selectin and ICAM-1 on endothelial cells of blood vessels. 
P-selectin is a cell adhesion molecule (CAM), expressed on endothelial 
cells and is stored on membranes of endothelial Weibel-Palade bodies and 
platelet α-granules (Wang et al., 2007). P-selectin mediates the binding of 
leukocytes such as neutrophils and monocytes (Gotsch et al., 1994), and also 
plays an important role in macrophage adhesion to blood vessels (Danton and 
Dietrich, 2003). Endothelial cells express selectins such as P-selectin and E-
selectin that interact with leukocyte counter receptors known as P-selectin 
glycoprotein ligand 1 (PSGL-1) and mediate the initial adhesion of leukocytes 






to vessel wall and their rolling along endothelial surfaces, before 
transmigrating from the blood into the tissues (Springer, 1995; Robinson et al., 
1999; Shigeta et al., 2008). During inflammatory process, P-selectin is rapidly 
translocated to the cell surface and binds to PSGL-1, which mediates the 
tethering and rolling process of leukocytes (Wang et al., 2007). Thus, 
upregulation of P-selectin by vasculature endothelium promotes inflammation 
by binding to circulating leukocytes, and facilitating their migration into the 
CNS (Danton and Dietrich, 2003). ICAM-1 is also a cell adhesion molecules, 
expressed on the surface of endothelial cells (Antonelli et al., 2001), and is a 
marker for endothelial dysfunction (Krska et al., 2003) and systemic 
inflammation (Mateos-Careres et al., 2002). ICAM-1 plays an important role in 
immune-mediated cell-cell adhesive interactions, intracellular signal 
transduction pathways through outside-in signaling events, and may play a 
primary role in regulating blood-brain barrier (BBB) function and structure 
(Huber et al., 2006). ICAM-1 binds to lymphocyte function-associated antigen 
1 (LFA-1) and macrophage 1 antigen (Mac-1) (Diamond et al., 1991), and 
both integrins contribute to slowing down of leukocytes rolling, and efficiently 
inducing firm adhesion (Dunne et al., 2002). Thus, similar to P-selectin, 
upregulation of ICAM-1 may enhance the migration of leukocytes into the 
CNS (Danton and Dietrich, 2003). 
 Besides P-selectin and ICAM-1, vWF was also upregulated in the 
brainstem after facial carrageenan-induced inflammatory pain. vWF is stored 
together with P-selectin in the endothelial Weibel-Palade bodies and is 
secreted in response to the same signals that externalize P-selectin (Pendu et 






al., 2006). It was demonstrated that vWF was able to interact with 
polymorphonuclear leukocytes (PMNs) and monocytes under static and flow 
conditions by providing binding sites for leukocyte receptors in rolling (PSGL-
1) (Pendu et al., 2006). Thus, upregulation of vWF in this study may support 
P-selectin in the rolling and stable adhesion steps in interaction with 
leukocytes, and the subsequent infiltration of leukocytes into the CNS. 
Increased in expression of chemokine-related genes, chemokine (C-C motif) 
ligand 12 (CCL12), was also observed in the microarray data. CCL12 also 
known as monocyte chemoattractant protein 5 (MCP-5), is a family of 
cytokines that control the recruitment of leukocytes in immune and 
inflammatory responses (Sarafi et al., 1997). This suggests that CCL12 may 
mediate the recruitment of leukocytes to the endothelial cells of blood vessel 
for the adhesion of P-selectin and ICAM-1, and subsequent transmigration of 
leukocytes into the CNS. 
Increased P-selectin and ICAM-1 expression might result in recruitment 
of blood monocytes to the brain (Ling, 1979), where they could produce pro-
nociceptive substances in the CNS, such as superoxide (Cathcart, 2004), or 
peroxynitrite (Yeo et al., 2008). P-selectin is required for firm adhesion and 
subsequent infiltration of leukocytes, and that P-selectin-mediated rolling is a 
prerequisite for ICAM-1-independent stationary adhesion (Thorlacius and 
Zhang, 1999). Thus, targeting P-selectin function may be a useful way to 
reduce infiltration of leukocytes. A possible role of P-selectin in the 
development of mechanical allodynia after facial carrageenan injection was 
elucidated. Facial carrageenan-injected mice that received daily 






intraperitoneal injection of P-selectin inhibitor showed decreased nociception, 
demonstrated by decreased responses to von Frey hair. These findings 
support the notion that increased P-selectin expression contributes to pro- 
rather than anti- nociception, probably through the enhancement of 
macrophages / monocytes entry into the brain. This is consistent with 
previous study, which showed prolonged macrophages / monocytes reaction 
in the caudal spinal trigeminal nucleus after facial formalin injection (Yeo et 
al., 2001). 
Leukocyte migration is known to affect the pathophysiology of 
inflammatory disease processes (Griffis et al., 2007). Studies have shown that 
acute pain induces increased CAM expression on leukocytes, which suggest 
increasing leukocyte infiltration and disease exacerbation in patient 
populations with inflammatory syndromes (Griffis et al., 2007). Similarly in this 
study, increased expression of endothelial CAMs (P-selectin and ICAM-1) 
was observed after facial carrageen-induced inflammatory pain. This 
increased expression of P-selectin and ICAM-1 may result in transmigration of 
leukocytes into the CNS where they could produce pro-nociceptive 



























Chapter 2.2 Gene expression analysis of the 
































1. Introduction 	   Multiple cortical regions have been associated with the experience of 
pain. These regions include the primary and secondary somatosensory 
cortices, anterior cingulate cortex, insular cortex, and regions of the frontal 
cortex (Bushnell et al., 1999).	   Although the sensory cortex plays an important 
role in pain processing, the prefrontal cortex was chosen in this study. This is 
because recent studies have shown an association of increased PFC activity 
with analgesia. Thus, the prefrontal cortex after orofacial pain was selected for 
gene expression microarray study in hope to find genes that are involved in 
analgesia or antinociception. 
Functional neuroimaging and connectivity analyses suggest that 
increases in the activity of prefrontal and cingulate cortices decrease pain 
perception via the descending pain inhibitory system (Valet et al., 2004; Xie et 
al., 2009). This pathway involves the periaqueductal grey (Mayer and Price, 
1976; Brooks and Tracey, 2005), which when stimulated produces behavioral 
analgesia in rats, cats, monkeys and humans (Basbaum and Fields, 1984; Cui 
et al., 1999) through descending influences that decrease the sensitivity of 
dorsal horn neurons to afferent noxious stimuli (Liebeskind et al., 1973). 
Activation of the prefrontal cortex is seen consistently in acute and chronic 
pain, and models of experimental pain (Ingvar, 1999; Peyron et al., 2000; 
Maihofner et al., 2004; Maihofner and Handwerker, 2005). Functional 
neuroimaging of the PFC also shows increased activity during expectation of 
analgesia following the administration of placebo, which in turn implicates its 
involvement in the cognitive control of pain (Petrovic et al., 2002; Benedetti et 






al., 2005; Wager, 2005; Ramos, 2007). In addition, recent use of transcranial 
magnetic stimulation of the motor cortex can result in clinically significant pain 
reduction (Lefaucheur et al., 2004; Lin et al., 2012). 
The more recent literature recognizes the significant role of the immune 
system, microglia and astrocytes in the development of pain hypersensitivity 
(DeLeo et al., 2004; Scholz and Woolf, 2007; Ren and Dubner, 2008). 
Immune cells, glia and neurons form an integrated network in which activation 
of an immune response modulates the excitability of pain pathways (Ren and 
Dubner, 2010). Immune cells can also exert an inhibitory effect on pain by 
releasing factors such as opioids and β-endorphin that enhance tissue 
recovery, suppress inflammation and reduce pain (Rittner et al., 2008; Hua 
and Cabot, 2010; Ren and Dubner, 2010). In addition, microglia and 
astrocytes are immunocompetent cells that respond like immune cells within 
the CNS (Watkins and Maier, 1999). They release substances that influence 
neuronal activity, indicating glia-neuron interactions (Ren and Dubner, 2010). 
Despite the importance of PFC in pain and analgesia, little is known 
about the associated gene expression changes induced by pain. Moreover, 
little or no microarray studies on pain were done in the prefrontal cortex. The 
present study was therefore carried out using a microarray-based approach to 
examine global gene expression changes in the prefrontal cortex in a mouse 
facial carrageenan injection model of orofacial pain. 
Increased expression of several genes was observed in the 
contralateral prefrontal cortex three days after facial carrageenan injection. 






Genes associated with immune system process; particularly S100a8, S100a9 
and Lcn2 were selected for further analysis. Real-time RT-PCR was carried 
out to validate the microarray results at the gene level, and Western blot 
analysis and immunohistochemistry were performed to validate the increased 
expression of S100A8, S100A9 and LCN2 at the protein level. Double 
immunofluorescence labeling was used to determine the expression of 
S100A8, S100A9 and LCN in neutrophils. Lastly, the function of S100A9 was 
examined by intracortical injection of a synthetic murine peptide of S100A9 
into the prefrontal cortex and the results showed that increased levels of 
S100A9 induce an antinociceptive effect in the prefrontal cortex demonstrated 
by a decreased in pain behavioral response of facial carrageenan-injected 
mice. 
 
2. Materials and methods 
2.1. Experimental animals 
Overall, 156 adult male C57BL/6J (B6) mice were used in the following 
series of experiments, and all procedures performed on these animals were 
as previously described (Chapter 2.1, Section 2.1). 
 
2.2. Facial carrageenan injection 
Treated mice were injected with 50 µl carrageenan (2 mg / 50 µl saline 
of lambda carrageenan, Sigma-Aldrich, St. Louis, MO, USA) in the facial 






region and all procedures performed on these animals were as previously 
described (Chapter 2.1, Section 2.2). 
 
2.3. Assessment of responses to mechanical stimulations 
 Behavioral assessments were carried out in a blinded manner as 
previously described (Chapter 2.1, Section 2.3). 
 
2.4. Microarray data collection and analysis 
A total of 16 independent samples were used, and none were pooled. 
The samples were divided into four treatment groups (four mice per group) – 
four for the right half of the prefrontal cortex of mice receiving left-sided facial 
carrageenan injection, four for the right prefrontal cortex of untreated controls, 
and similarly for the left half of the prefrontal cortex of mice receiving right-
sided facial carrageenan injection and its corresponding controls. Mice were 
anaesthetized and decapitated. Brains were harvested and olfactory bulbs 
removed. The mouse brain were placed in a mouse brain matrix and a small 
cut was made 1.50 mm from the tip of the frontal pole to mark the area of the 
prefrontal cortex. The brain were then removed from the matrix and the left 
and right prefrontal cortices dissected out using a scalpel according to the 
markings made using the matrix. The harvesting of the prefrontal cortices 
were performed consistently for all other samples and the area of the PFC 
dissected out is delimited by the vertical lines (Figure 3.10). The subsequent 
gene expression profiling of the tissues and analysis of the microarray data 
were performed as previously described (Chapter 2.1, Section 2.4) 








Figure 3.10. Lateral view of a mouse brain. The extent of the prefrontal 
cortex is delimited by the vertical lines. 
 
 
2.5. Real-time RT-PCR 
The same RNA extracted for the microarray analysis (n = 16) together 
with a new batch of samples (n = 16) were used for the validation of 
microarray results. A further twelve mice were used for the study of 
differences in gene expression changes in PFC of perfused vs non-perfused 
mice. The 12 mice were divided into three groups – left facial carrageenan 
injected mice perfused with saline (n = 4), control mice perfused with saline (n 
= 4) and left facial carrageenan injected mice (n = 4). Blood (100 µl) were 
collected from the heart before perfusion, stored in RNAprotect® Animal 
Blood Tubes (Qiagen, Inc., CA, USA) and RNA extracted using RNeasy 
Protect Animal Blood Kit (Qiagen, Inc., CA, USA) according to manufacturer’s 
protocol. The subsequent reverse transription and real-time RT-PCR 
experiment were performed as previously described (Chapter 2.1, Section 
2.5), using the following gene-specific primers and probes: S100a8 






(Mm00496696_g1), S100a9 (Mm00656925_m1), Lcn2 (Mm01324470_m1), 
Ccl12 (Mm01617100_m1), Il2rg (Mm00442885_m1), Fcgr1 
(Mm00438874_m1), Fcgr2b (Mm00438875_m1), Ptprc (Mm01293575_m1), 
C1qb (Mm01179619_m1), C1qr1 (Mm00440239_g1), Cfh 
(Mm01299243_m1), Cd52 (Mm00489055_m1), Nfkbia (Mm00477798_m1) 
and Igh6 (Mm01718955_g1, all from Applied Biosystems, CA, USA). 
 
2.6. Western blot analysis 
A further eight mice were used for this portion of the work. Four mice 
were injected with carrageenan on the left side of the face and sacrificed 3 
days after injection, and the remaining four mice were used as controls. The 
mice were sacrificed and the right prefrontal cortex removed. The subsequent 
protein extraction and western blot analysis were performed as previously 
decribed (Chapter 2.1, Section 2.6), using 50 μg of homogenates and goat 
polyclonal antibodies to S100A8 (sc-8113, Santa Cruz Biotechnology, CA, 
USA; diluted 1:50), S100A9 (sc-8115, Santa Cruz Biotechnology, CA, USA; 
diluted 1:50) and LCN2 (AF3508, R&D System, MN, USA, diluted 1:200. 
 
2.7. Double immunofluorescence labeling 
Eight adult male mice were used for this portion of the study. Four mice 
were injected with carrageenan on the left side of the face, and four were 
used as controls. Mice were sacrificed after 3 days by deep anaesthesia. The 
brains were dissected out, and the olfactory bulb removed with a scalpel. The 
brains were then embedded in an embedding matrix and trimmed with the 






freezing microtome until the sign of prefrontal cortex was observed (3.20 mm 
caudal to bregma) (Figure 3.11). 40 to 50 sections each of 12 µm were 
collected, and one in six sections were selected for immunohistochemistry. 
Immunohistochemistry was performed on the 12 µm fresh frozen sections, 
which were fixed for 10 min in 4% paraformaldehyde at room temperature and 
subjected to antigen retrieval by heating at 95-99oC in Dako target retrieval 
solution for 20 min, followed by three washes in PBS. The subsequent steps 
were performed as previously described (Chapter 2.1, Section 2.8), using goat 
polyclonal antibodies to S100A8 (sc-8113, Santa Cruz, CA, diluted 1:100 in 
PBS), S100A9 (sc-8115, Santa Cruz, CA, diluted 1:100 in PBS), LCN2 (sc-
18698, Santa Cruz, CA, diluted 1:100 in PBS) and rabbit polyclonal antibody 
to myeloperoxidase (MPO) (ab9535, Abcam, Cambridge, UK, diluted 1:100 in 
PBS). The secondary antibodies used were Alexa Fluor 488 anti-goat IgG and 
Alexa Fluor 555 anti-rabbit IgG (Invitrogen, CA, USA). Finally, sections were 
mounted and examined using a Zeiss LSM 510 confocal microscope (Carl 
Zeiss Inc., USA). The region of the PFC examined is demarcated by the 
dotted box in Figure 3.11. 







Figure 3.11. Diagram showing the sign of prefrontal cortex, which was used 
as a landmark to obtain comparable sections for immunohistochemistry. The 
dotted box indicates the approximate region where images in Figure 3.16 
and 3.17 were obtained. 
 
2.8. Synthesis of S100A9 peptide 
A peptide identical to the C-terminus of murine S100A9 protein 
(mS100A9p) (H-E-K-L-H-E-N-N-P-R-G-H-G-H-S-H-G-K-G) was synthesized 
by GenScript USA Inc. based on previously published sequence (Raftery et 
al., 1996). This peptide was synthesized in solid phase by the 
fluorenylmethyloxycarbonyl (FMOC) technique. The characterization and 
purification of the peptide was carried out by HPLC, and its mass evaluated by 
ESI-MS. The peptide was diluted in saline at a final concentration of 2 mg/ml.  
 
2.9. Effect of mS100A9p administration 
12 groups of mice were used in this portion of the study. The 
antinociceptive effect of mS100A9p were examined in different regions of the 
brain, (i) intracerebroventricular (i.c.v.) injection, (ii) intracortical (i.c.) injection 






of the prefrontal cortex, and (iii) intracortical injection of the barrel 
somatosensory cortex. 
 
2.9.1. Intracerebroventricular mS100A9p injection 
 A total of 40 mice divided into five groups of eight mice each were used 
in this portion of the work. Two groups received left facial carrageenan 
injection and bilateral intracerebroventricular injection of 2 µg/µl or 0.25 µg/µl 
of mS100A9p (GeneScript, NJ, USA) in a volume of 1 µl each into both left 
and right lateral ventricle on the third day after facial carrageenan injection 
(coordinates: 0.7 mm caudal to bregma, 1.0 mm lateral to the midline, 2.0 mm 
from the surface of the cerebral cortex) (Yeo et al., 2004). Another group (8 
mice) received left facial carrageenan injection and bilateral 
intracerebroventricular injection of saline (vehicle control) on the third day 
after facial carrageenan injection. The remaining two groups (8 mice per 
group) were control groups (without facial carrageenan injection) that received 
bilateral intracerebroventricular injection of 2 µg/µl of mS100A9p or saline in a 
volume of 1 µl each into both left and right lateral ventricle on the third day. 
Responses to von Frey hair stimulation were quantified daily in a blinded 
manner. Mean and standard errors of the total responses were then 
calculated for each experimental group, and possible significant differences 
between the means were examined using one-way ANOVA with Bonferroni 
multiple comparison test. P < 0.05 was considered significant. 
 






2.9.2. Prefrontal cortex mS100A9p injection 
 A total of 40 mice divided into five groups of eight mice each were used 
in this portion of the work. Two groups received left facial carrageenan 
injection and bilateral intracortical injection of 2 µg/µl or 0.5 µg/µl of 
mS100A9p in a volume of 0.5 µl each into both left and right dorsolateral 
prefrontal cortex on the third day after facial carrageenan injection 
(coordinates: 2.5 mm rostral to bregma, 1.5 mm lateral to the midline, 1.5 mm 
from the surface of the cerebral cortex) (Paxinos and Franklin, 2004). The 
doses were determined based on a pilot study using a small number of 
animals. Another group (8 mice) received left facial carrageenan injection and 
bilateral intracortical injection of saline (vehicle control) on the third day after 
facial carrageenan injection. The remaining two groups (8 mice per group) 
were control groups (without facial carrageenan injection) that received 
bilateral intracortical injection of 2 µg/µl of mS100A9p or saline in a volume of 
0.5 µl each into both left and right dorsolateral prefrontal cortex on the third 
day. Responses to von Frey hair stimulation were quantified daily in a blinded 
manner. Mean and standard errors of the total responses were then 
calculated for each experimental group, and possible significant differences 
between the means were examined using one-way ANOVA with Bonferroni 
multiple comparison test. P < 0.05 was considered significant. 
 
2.9.3. Somatosensory cortex mS100A9p injection 
An additional two groups of 8 mice each were used to study the effect 
of mS100A9p in the barrel somatosensory cortex. The same dose as the 






prefrontal cortex injections was used. The two groups received left facial 
carrageenan injection and bilateral i.c. injection of either 2 µg/µl of mS100A9p 
or saline in a volume of 0.5 µl into both left and right barrel somatosensory 
cortex on the third day after facial carrageenan injection (coordinates: 1.5 mm 
caudal to bregma, 3 mm lateral to the midline, 1.5 mm from the surface of the 
cerebral cortex) (Paxinos and Franklin, 2004). Responses to von Frey hair 
stimulation were quantified daily in a blinded manner. Mean and standard 
errors of the total responses were then calculated for each experimental 
group, and possible significant differences between the means were 
examined using one-way ANOVA with Bonferroni multiple comparison test. P 
< 0.05 was considered significant. The different treatment groups are 












































mS100A9p Saline 2 μg/μl 1 μl 8 
mS100A9p Saline 0.25 μg/μl 1 μl 8 
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mS100A9p Saline 0.5 μg/μl 0.5 μl 8 
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3.1. Microarray analysis 
 Facial carrageenan-injected mice showed increasing response 
behaviors to stimulation with the von Frey hair up to the third day after 
carrageenan injection, with significantly increased responses compared to 
control mice at post-injection days 1, 2 and 3 (Figure 3.12). They were 
sacrificed on the third day after facial carrageenan injection (time of 
approximate peak nociceptive response), and the prefrontal cortices were 
harvested for microarray analysis. 
 
 
Figure 3.12. Responses to von Frey hair stimulation of the face after facial carrageenan 
injection. (A) Left-sided facial carrageenan injection. (B) Right-sided facial carrageenan 
injection. The Y axis represents number of responses to von Frey hair stimulation of the 
carrageenan injected areas of the face. BI: before injection, 1D, 2D, 3D refer to 1 day, 2 days, 
and 3 days after injection. Control: untreated control. Carrageenan: after facial carrageenan 
injection. Analyzed by Studentʼs t-test. Asterisks indicate significant difference at p-value of 
<0.05 (*), <0.01 (**), and <0.001 (***). 
 
Gene expression profiles of the right prefrontal cortices in mice that 
received left facial carrageenan injection were compared to the corresponding 
data of untreated controls. A total of 194 genes were altered at a fold change 
≥1.5 (p-value < 0.05). Similarly, gene expression profiles of the left prefrontal 
cortices in mice that received right facial carrageenan injection were 
compared to data obtained from untreated controls. A total of 467 genes were 






altered at a fold change of ≥1.5 (p-value < 0.05). Common genes between the 
differentially expressed genes in the left PFC (467 genes) and the right PFC 
(194 genes) were identified. This step was undertaken to increase the yield 
for greater pain-related specificity, minimizing the impact of false positives and 
to disregard possible side-specific changes in the PFC. The result was a list of 
76 genes, of which genes with uncertain ontology were ignored, leaving 52 
known genes that had more than 1.5-fold change (Table 3.5). 
 
Gene Gene Symbol 
Fold Change 
in Right PFC  
(Mean ± SD) 
P-value 
Fold Change 
in Left PFC     
(Mean ± SD) 
P-value 
S100 calcium binding protein A8* S100a8 20.7 ± 5.6 3.8E-05 7.5 ± 4.6 0.0022 
Lipocalin 2* Lcn2 16.1 ± 0.9 0.018 10.4 ± 8.1 0.0023 
S100 calcium binding protein A9* S100a9 15.0 ± 5.3 0.00017 9.1 ± 5.4 0.0046 
Interferon, alpha-inducible protein 27  Ifi27 3.9 ± 0.7 0.00050 3.0 ± 0.9 0.0019 
Von Willebrand factor homolog vWF 3.7 ± 1.2 0.0040 2.3 ± 0.3 0.00078 
Secretoglobin, family 3A, member 1 Scgb3a1 2.8 ± 1.0 0.0041 2.4 ± 1.4 0.047 
Lysozyme Lyzs 2.7 ± 0.8 0.0023 2.2 ± 0.3 0.00033 
Interferon induced transmembrane 
protein 3 Ifitm3 2.4 ± 0.3 0.0010 2.3 ± 0.1 0.00019 
Trophoblast specific protein beta Tpbpb 2.4 ± 0.5 0.0034 1.6 ± 0.2 0.00044 
Transglutaminase 2, C polypeptide Tgm2 2.4 ± 0.1 0.0098 2.2 ± 0.5 0.0015 
Intercellular adhesion molecule Icam1 2.3 ± 0.6 0.010 1.7 ± 0.5 0.029 
Junction adhesion molecule 2 Jam2 2.3 ± 0.3 0.00050 2.8 ± 0.9 0.0026 
Peptidylprolyl isomerase C-associated 
protein Ppicap 2.2 ± 0.3 0.025 1.9 ± 0.5 0.0076 
Breast carcinoma amplified sequence 2 Bcas2 2.2 ± 0.5 0.029 1.6 ± 0.2 0.0023 
Chemokine (C-C motif) ligand 12* Ccl12 2.2 ± 1.0 0.047 1.8 ± 0.5 0.012 
Ceruloplasmin Cp 2.1 ± 0.2 0.024 1.9 ± 0.5 0.013 
Nel-like 2 homolog (chicken) Nell2 2.1 ± 0.5 0.0089 5.0 ± 0.4 1.1E-06 
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
Ywhaz 2.1 ± 0.3 0.00069 1.8 ± 0.3 0.0022 
Histocompatibility 2, Q region locus 7 H2-Q7 2.1 ± 1.0 0.043 2.1 ± 0.3 0.00065 
Fc receptor, IgG, low affinity IIb* Fcgr2b 2.1 ± 0.3 0.0025 1.9 ± 0.3 0.0012 
Protein tyrosine phosphatase, 
receptor type, C* Ptprc 2.0 ± 0.3 0.0073 2.0 ± 0.1 0.0057 
Oncostatin M receptor Osmr 2.0 ± 0.4 0.0023 1.7 ± 0.6 0.033 
Interferon induced transmembrane 
protein 1 Ifitm1 2.0 ± 0.2 0.0045 1.7 ± 0.1 0.00047 
Interleukin 2 receptor, gamma chain* Il2rg 1.9 ± 0.1 0.00019 1.7 ± 0.4 0.017 
(Table continues on following page.) 







(Continued from previous page.) 
Gene Gene Symbol 
Fold Change 
in Right PFC  
(Mean ± SD) 
P-value 
Fold Change 
in Left PFC     
(Mean ± SD) 
P-value 
Receptor transporter protein 4 Rtp4 1.9 ± 0.4 0.0032 1.8 ±0.4 0.012 
Placenta-specific 8 Plac8 1.9 ± 0.7 0.039 1.7 ± 0.3 0.0048 
C-type lectin domain family 14, member a Clec14a 1.8 ± 0.4 0.0095 1.9 ± 0.3 0.013 
Lymphocyte antigen 6 complex, locus A Ly6a 1.8 ± 0.1 0.00049 1.6 ± 0.2 0.0019 
Complement component factor h Cfh 1.8 ± 0.2 0.00049 1.7 ± 0.3 0.0045 
Complement component 1, q 
subcomponent, beta polypeptide* C1qb 1.8 ± 0.1 0.016 1.5 ± 0.2 0.0054 
C-type lectin domain family 4, member a3 Clec4a3 1.8 ± 0.4 0.026 1.7 ± 0.5 0.025 
Integrin alpha 4 Itga4 1.7 ± 0.3 0.0036 1.9 ± 0.4 0.0055 
Fc receptor, IgG, high affinity I* Fcgr1 1.7 ± 0.4 0.0091 1.6 ± 0.3 0.01 
Claudin 5 Cldn5 1.7 ± 0.2 0.00056 1.8 ± 0.2 0.00028 
Suppressor of cytokine signaling 3 Socs3 1.7 ± 0.4 0.018 1.6 ± 0.2 0.0034 
Vimentin Vim 1.6 ± 0.04 0.0093 1.5 ± 0.1 0.0018 
Friend leukemia integration 1 Fli1 1.6 ± 0.2 0.0019 1.6 ± 0.2 0.041 
Immunoglobulin superfamily, member 7 Igsf7 1.6 ± 0.2 0.002 1.5 ± 0.2 0.001 
Zinc finger, ZZ domain containing 3 Zzz3 1.6 ± 0.5 0.036 1.5 ± 0.2 0.0078 
CD52 antigen* Cd52 1.6 ± 0.04 0.00067 1.6 ± 0.5 0.036 
Immediate early response 3 Ier3 1.6 ± 0.3 0.0093 1.6 ± 0.2 0.0084 
Family with sequence similarity 13, 
member C Fam13c 1.6 ± 0.2 0.0063 1.6 ± 0.1 0.000068 
Complement component 1, q 
subcomponent, receptor 1 C1qr1 1.5 ± 0.04 0.0091 1.6 ± 0.4 0.028 
Immunoglobulin heavy chain 6 (heavy 
chain of IgM) Igh6 -1.9 ± 0.1 0.0008 -2.2 ± 0.1 0.00028 
Serum/glucocorticoid regulated kinase Sgk -1.8 ± 0.1 0.0034 -1.9 ± 0.1 0.0072 
Arrestin domain containing 2 Arrdc2 -1.7 ± 0.2 0.028 -2.2 ± 0.1 0.016 
Polymerase (RNA) III (DNA directed) 
polypeptide C Polr3c -1.7 ± 0.1 0.0046 -1.5 ± 0.04 0.00014 
TATA box binding protein (Tbp)-
associated factor, RNA polymerase I, C Taf1c -1.6 ± 0.1 0.025 -1.7 ± 0.2 0.039 
Basic transcription element binding 
protein 1 Bteb1 -1.6 ± 0.1 0.032 -1.6 ± 0.1 0.025 
Nuclear factor of kappa light chain 
gene enhancer in B-cells inhibitor, 
alpha 
Nfkbia -1.6 ± 0.1 0.016 -1.7 ± 0.1 0.043 
Zinc finger protein 339 Zfp339 -1.6 ± 0.1 0.022 -1.8 ± 0.1 0.0016 
Glucocorticoid-induced leucine zipper Gilz -1.5 ± 0.1 0.0071 -1.6 ± 0.1 0.027 
Table 3.5. Differentially expressed genes in the contralateral prefrontal cortex after facial carrageenan 
injection. These are common genes that show upregulation or downregulation by more than 1.5-fold, 
after right or left-sided facial carrageenan injection, compared to prefrontal cortex of the respective 










These genes were categorized using the GO term enrichment analysis 
from the DAVID resource website, and sorted based on their Fisher Exact p-
value (Dennis et al., 2003; Huang da et al., 2009). The category with the 
lowest Fisher Exact p-value (12 of the 52 genes) was annotated with the GO-
term ʻʻimmune system processʼʼ (Fisher Exact p-value = 2.4E-6) and was 
selected for analysis. All 12 genes in this category, together with S100a8 and 
Lcn2, were selected for further validation. S100a8 and Lcn2 were included for 
further analysis because of their high fold-change observed in the microarray 
results, which they might play an important role in this pain study. Table 3.6 


































Term Gene counts Fisher Exact p-value 
Immune system process  12 2.40E-06 
Regulation of multicellular organismal process  8 6.70E-06 
Regulation of immune response  6 7.00E-06 
Regulation of immune system process  6 1.10E-05 
Cell activation  7 2.40E-05 
Immune effector process  6 2.40E-05 
Response to biotic stimulus  7 3.10E-05 
Lymphocyte mediated immunity  5 6.60E-05 
Regulation of lymphocyte activation 5 6.60E-05 
Adaptive immune response 5 8.20E-05 
Positive regulation of immune response 5 9.00E-05 
Positive regulation of immune system process  5 9.60E-05 
Adaptive immune response based on somatic 
recombination of immune receptors built from 
immunoglobulin superfamily domains  
5 9.60E-05 
Regulation of cell activation 5 9.90E-05 
Regulation of lymphocyte activation 5 1.00E-04 
Leukocyte mediated immunity 5 1.20E-04 
Response to external stimulus  8 1.40E-04 
Leukocyte activation  6 2.10E-04 
Positive regulation of multicellular organismal 
process  5 2.60E-04 
Positive regulation of lymphocyte activation  4 4.70E-04 
Table 3.6. Top 20 Gene Ontology (GO) terms of the 52 common genes. These genes were 
categorized using the GO-term enrichment analysis from the DAVID resource website, and 
sorted based on their Fisher Exact p-value. A p-value of equal or smaller than 0.05 is 
considered strongly enriched in the annotation categories. 
 
3.2. Validation of differentially expressed genes by real-time RT-PCR 
The results obtained from the microarray data analysis revealed the 
altered transcriptions of many genes after facial carrageenan injection. To 
validate the microarray data, the transcription levels in some of the 
microarray-identified genes were further determined using real-time RT-PCR. 
The genes that were chosen for validation by real-time RT-PCR were immune 
system process-related genes, which include S100a9, Ccl12, Il2rg, Fcgr1, 
Fcgr2b, Ptprc, C1qb, C1qr1, Cd52, Cfh, Igh6 and Nfkbia. In addition, S100a8 






and Lcn2 having the two highest fold change were also included for real-time 
RT-PCR validation. Besides validation of the microarray results of the 
contralateral prefrontal cortex, real-time RT-PCR of these genes was also 
performed in the ipsilateral prefrontal cortex. 
 
3.2.1. Contralateral prefrontal cortex 
Real-time RT-PCR was used to validate the results of the microarray 
analyses for the genes identified above. 10 out of 14 genes were validated, 
namely S100a8, S100a9, Lcn2, Il2rg, FcgrI, Fcgr2b, C1qb, Ptprc, Ccl12 and 
Cd52. The relative fold changes of S100a8, S100a9, Lcn2, Il2rg, FcgrI, 
Fcgr2b, C1qb, Ptprc, Ccl12 and Cd52 for the right PFC after left facial 
carrageenan injection were 12.6, 10.6, 24.0, 2.3, 1.7, 2.1, 1.6, 2.5, 2.1 and 
1.9, respectively (Figure 3.13A), while the relative fold changes for the left 
PFC after right facial carrageenan injection were 29.0, 29.6, 26.3, 2.8, 2.1, 
2.7, 1.8, 2.5, 3.4 and 2.6, respectively (Figure 3.13B). Genes that were 
validated showed similar transcription alteration patterns between the real-
time RT-PCR and the microarray assays, which further confirmed the 
consistency of the results, indicating a high reliability of the microarray data 
obtained in this study. 







Figure 3.13. Real-time RT-PCR analysis of differentially expressed genes in 
the contralateral prefrontal cortex after facial carrageenan injection. S100a8, 
S100a9, Lcn2, Il2rg, Fcgr1, Fcgr2b, C1qb, Ptprc, Ccl12 and Cd52 in the 
mouse prefrontal cortex after facial carrageenan injection. (A) Left-sided 
facial carrageenan injection. (B) Right-sided facial carrageenan injection. 
Control: untreated control. Carrageenan: after facial carrageenan injection. 
Analyzed by Studentʼs t-test. Asterisks indicate significant difference at p-
value of <0.05 (*), <0.01 (**), and <0.001 (***). 
 
3.2.2. Ipsilateral prefrontal cortex  
Real-time RT-PCR analyses of the ipsilateral PFC, showed similar 
increases in gene expression compared to data established for the 
contralateral PFC. The relative fold changes of S100a8, S100a9, Lcn2, Il2rg, 
FcgrI, Fcgr2b, C1qb, Ptprc, Ccl12 and Cd52 for the left PFC after left facial 
carrageenan injection were 15.2, 16.4, 24.8, 2.8, 2.0, 2.7, 1.8, 2.3, 2.8 and 






2.3, respectively (Figure 3.14A), while the relative fold changes for the right 
PFC after right facial carrageenan injection were 16.8, 12.4, 18.8, 2.8, 2.0, 
2.2, 1.8, 3.2, 3.1 and 2.6, respectively (Figure 3.14B). 
 
Figure 3.14. Real-time RT-PCR analysis of differentially expressed genes in 
the ipsilateral prefrontal cortex after facial carrageenan injection. S100a8, 
S100a9, Lcn2, Il2rg, Fcgr1, Fcgr2b, C1qb, Ptprc, Ccl12 and Cd52 in the 
mouse prefrontal cortex after facial carrageenan injection. (A) Left-sided 
facial carrageenan injection. (B) Right-sided facial carrageenan injection. 
Control: untreated control. Carrageenan: after facial carrageenan injection. 
Analyzed by Studentʼs t-test. Asterisks indicate significant difference at p-











3.3. Western blot analysis of S100A8, S100A9 and LCN2 
 Western blot analysis of extracts from the right prefrontal cortex of left 
facial carrageenan-injected mice detected bands of S100A8 and S100A9 at 
around 10 kDa and 13 kDa, respectively, consistent with the expected 
molecular weights of these proteins (Grimbaldeston et al., 2003; Johansson et 
al., 2008). Antibody to LCN2 detected a single band at around 23 kDa, 
consistent with the expected molecular weights (Yan et al., 2007). No band 
was detected in the negative control, with protein samples of facial 
carrageenan-injected mice incubated with only secondary antibodies. The 
antibody to β-actin reacted against a band at 42 kDa. Significant increase in 
the density ratios of S100A8, S100A9 and LCN2 to β-actin bands was 
observed in Western blots of 3 days post carrageenan-injected mice, 
compared to the control mice. The relative density of S100A8, S100A9 and 






























Figure 3.15. Western blot analysis of (A) S100A8, (B) S100A9 and (C) LCN2 in homogenates 
of the contralateral prefrontal cortex from 3 days post facial carrageenan-injected mice and 
control mice. (D-F) S100A8, S100A9 and LCN2 are increased in facial carrageenan injected 
mice as determined by band intensity quantification normalized to β-actin, and analyzed by 
Studentʼs t-test. Asterisks indicate significant difference at p-value of <0.05 (*), <0.01 (**), and 
<0.001 (***). 
 
3.4. Immunohistochemistry of S100A8, S100A9 and LCN2 
Immunofluorescent staining for S100A8, S100A9 and LCN2 proteins 
showed very few or no immunopositive cells in the PFC of control mice 
(Figure 3.16A-C). However, increased immunopositive cells for S100A8, 
S100A9 and LCN2 were observed in the PFC of 3 days post carrageenan-
injected mice (Figure 3.16D-F, green, white arrows). 
 







Figure 3.16. Facial carrageenan-induced inflammation causes an increase in the number of 
S100A8, S100A9 and LCN2-immunoreactive cells in the prefrontal cortex. (A-C) Minimal 
staining was observed for S100A8, S100A9 and LCN2, respectively, in the contralateral 
prefrontal cortex of control mice. (D-F) Increased immunopositive cells were observed for 
S100A8, S100A9 and LCN2, respectively, in the contralateral prefrontal cortex of 3 days post 
facial carrageenan-injected mice. Scale: A-F = 400 µm. 
 
Higher magnification suggests that the staining of S100A8 was mostly 
observed in the cytoplasm (Figure 3.17A, green). Double labeling of S100A8 
with myeloperoxidase (MPO, a neutrophil marker) (Figure 3.17B, red), 
showed colocalization of S100A8 with MPO, indicating expression of S100A8 
in the neutrophils (Figure 3.17C, arrows). Similarly, the staining of S100A9 
was observed in the cytoplasm (Figure 3.17D, green). Double labeling of 
S100A9 with MPO (Figure 3.17E, red), showed colocalization of S100A9 with 
MPO, indicating expression of S100A9 in the neutrophils (Figure 3.17F, 
arrows). The staining of LCN2 was also observed in the cytoplasm (Figure 
3.17G, green). Double labeling of LCN2 with MPO (Figure 3.17H, red), 
showed colocalization of LCN2 with MPO, indicating expression of LCN2 in 
the neutrophils (Figure 3.17I, arrows). 







Figure 3.17. Localization of S100A8, S100A9 and LCN2. (A) S100A8-immunopositve cells 
(green) and (B) MPO-immunopositive cells (red) were detected in the contralateral prefrontal 
cortex of 3 days post facial carrageenan-injected mice. (C) Double labeling with antibodies 
against S100A9 and MPO showed colocalization of S100A8 with MPO (arrows).  (D) S100A9-
immunopositve cells (green) and (E) MPO-immunopositive cells (red) were detected in the 
contralateral prefrontal cortex of 3 days post facial carrageenan-injected mice. (F) Double 
labeling with antibodies against S100A9 and MPO showed colocalization of S100A8 with 
MPO (arrows). (G) LCN2-immunopositve cells (green) and (H) MPO-immunopositive cells 
(red) were detected in the contralateral prefrontal cortex of 3 days post facial carrageenan-
injected mice.  (I) Double labeling with antibodies against LCN2 and MPO showed 
colocalization of LCN2 with MPO (arrows). Scale: A-I = 20 µm. 
 
 
3.5. Comparison of perfused vs non-perfused brain and findings from 
blood 
3.5.1. Real-time RT-PCR findings from brain 
Real-time RT-PCR was carried out to determine any differences 
caused by perfusion of the animals. Similar to non-perfused samples, 






significant increased in the expression of S100a8, S100a9, Lcn2, Il2rg, FcgrI, 
Fcgr2b, C1qb, Ptprc, Ccl12, Cd52 and Mpo in the right PFC of perfused mice 
were found after left facial carrageenan injection, compared to perfused 
control mice. The relative fold changes were 15.3, 16.7, 28.6, 2.1, 2.1, 1.9, 
1.7, 1.8, 3.1, 2.4 and 2.8, respectively. No significant differences were 
observed when non-perfused PFC were compared to perfused PFC. 
Together, the results indicate that the increased expression of the immune 
process-related genes is contributed by cells within the brain parenchyma and 
not primary those in the brain vasculature (Figure 3.18). 
 
Figure 3.18. Effects of perfusion on the immune process-related genes in the mouse 
prefrontal cortex after facial carrageenan injection. Analyzed by one-way ANOVA with 
Bonferroni multiple comparison test. Asterisks indicate significant difference compared to 
untreated, non-perfused controls at p-value of <0.05 (*), <0.01 (**), and <0.001 (***). 
 
3.5.2. Real-time RT-PCR findings from blood 
 Significantly increased in the expression of S100a8, S100a9, Lcn2, 
FcgrI, Cd52 and Mpo was detected in the blood of 3 days post facial 
carrageenan-injected mice compared to control mice. The relative fold 
changes were 9.9, 6.7, 18.4, 3.6, 2.7 and 4.4 respectively. The remaining 






genes that were not significantly altered in the blood include Il2rg, Fcgr2b, 
C1qb, Ptprc and Ccl12 (Figure 3.19). 
 
Figure 3.19. Results from blood. Analyzed by Studentʼs t-test. Asterisks indicate significant 
difference at p-value of <0.05 (*), <0.01 (**), and <0.001 (***). 
 
 
3.6. Effect of mS100A9p treatment on pain behavioral responses 
3.6.1. Intracerebroventricular mS100A9p injection 
Mice infused intracerebroventricularly into the lateral ventricles with 
mS100A9p and without facial carrageenan injection were unaffected, showing 
no difference in response behavior from baseline data. Experimental mice that 
were infused intracerebroventricularly into the lateral ventricles on the third 
day after facial carrageenan injection with 2 µg of mS100A9p (per side), 
showed significant difference in pain response 12 hrs after i.c.v. injection, 
compared to facial carrageenan-injected mice infused with saline (Figure 
3.20). These effects were no longer observed from the fourth day onwards. 
Facial carrageenan-injected mice treated with a lower dose, i.e. 0.25 µg of 
mS100A9p (per side), showed no significant difference from those injected 






with saline plus facial carrageenan injection at all times, thus mS100A9p was 
ineffective in modulating mechanical allodynia at the lower dose. 
 
Figure 3.20. Responses to von Frey hair stimulation of the face after tissue inflammation 
induced by carrageenan injection after i.c.v. injection of mS100A9p into the lateral ventricles. 
The Y-axis represents number of responses to von Frey hair stimulation of the carrageenan-
injected areas of the face. BI: before injection, 1D to 12D refer to 1 day to 12 days after 
injection. Control + Saline (vehicle): control and i.c.v. saline injection. Control + mS100A9 (2 
µg): control and i.c.v. injection of 2 µg mS100A9. Carrageenan + Saline (vehicle): facial 
carrageenan injection and i.c.v. saline injection. Carrageenan + mS100A9p (2 µg): facial 
carrageenan injection and i.c.v. injection of 2 µg mS100A9p. Carrageenan + mS100A9p (0.25 
µg): facial carrageenan injection and i.c.v. injection of 0.25 µg mS100A9p. Analyzed by one-
way ANOVA with Bonferroni multiple comparison test. Mice treated with Carrageenan + 
mS100A9p (2 µg) showed statistically significant difference against mice treated with 
Carrageenan + Saline (vehicle), 12 hrs after mS100A9p injection on the 3rd day after facial 
carrageenan injection (P < 0.05). However, mice treated with Carrageenan + mS100A9p 
(0.25 µg) showed no statistical difference from mice treated with Carrageenan + Saline 
(vehicle) at all times. Asterisks indicate significant difference at p-value of <0.05 (*), <0.01 
(**), and <0.001 (***). 
 
3.6.2. Prefrontal cortex mS100A9p injection 
 Mice infused intracortically into the dorsolateral prefrontal cortices with 
mS100A9p and without facial carrageenan injection were unaffected, showing 
no difference in response behavior from baseline data. Experimental mice that 
were infused intracortically into the dorsolateral prefrontal cortices on the third 
day after facial carrageenan injection with 1 µg of mS100A9p (per side), 






showed significant difference in pain response 12 hrs after i.c. injection, 
compared to facial carrageenan-injected mice infused with saline (Figure 
3.21). These effects were no longer observed from the fourth day onwards. 
Facial carrageenan-injected mice treated with a lower dose, i.e. 0.25 µg of 
mS100A9p (per side), showed no significant difference from those injected 
with saline plus facial carrageenan injection at all times, thus mS100A9p was 
ineffective in modulating mechanical allodynia at the lower dose. 
 
 
Figure 3.21. Responses to von Frey hair stimulation of the face after tissue inflammation 
induced by carrageenan injection after i.c. injection of mS100A9p into the prefrontal cortices. 
The Y-axis represents number of responses to von Frey hair stimulation of the carrageenan-
injected areas of the face. BI: before injection, 1D to 12D refer to 1 day to 12 days after 
injection. Control + Saline (vehicle): control and i.c. saline injection. Control + mS100A9 (1 
µg): control and i.c. injection of 1 µg mS100A9. Carrageenan + Saline (vehicle): facial 
carrageenan injection and i.c. saline injection. Carrageenan + mS100A9p (1 µg): facial 
carrageenan injection and i.c. injection of 1 µg mS100A9p. Carrageenan + mS100A9p (0.25 
µg): facial carrageenan injection and i.c. injection of 0.25 µg mS100A9p. Analyzed by one-
way ANOVA with Bonferroni multiple comparison test. Mice treated with Carrageenan + 
mS100A9p (1 µg) showed statistically significant difference against mice treated with 
Carrageenan + Saline (vehicle), 12 hrs after mS100A9p injection on the 3rd day after facial 
carrageenan injection (P < 0.05). However, mice treated with Carrageenan + mS100A9p 
(0.25 µg) showed no statistical difference from mice treated with Carrageenan + Saline 
(vehicle) at all times. Asterisks indicate significant difference at p-value of <0.05 (*), <0.01 
(**), and <0.001 (***). 
 






3.6.3. Somatosensory cortex mS100A9p injection 
Additional study was carried out to examine if intracortical injection of 
mS100A9p into the barrel somatosensory cortices will have similar effect to 
that injected into the prefrontal cortex. Facial carrageenan-injected mice 
infused intracortically with 1 µg of mS100A9p (per side) into the barrel 
somatosensory cortices showed no significant difference from those injected 
with saline plus facial carrageenan injection at all times. Thus, the results 
indicate that mS100Ap was ineffective in modulating mechanical allodynia 




Figure 3.22. Responses to von Frey hair stimulation of the face after tissue inflammation 
induced by carrageenan injection after i.c. injection of mS100A9p into the barrel 
somatosensory cortices. The Y-axis represents number of responses to von Frey hair 
stimulation of the carrageenan-injected areas of the face. BI: before injection, 1D to 12D refer 
to 1 day to 12 days after injection. Carrageenan + Saline (vehicle): facial carrageenan 
injection and i.c. saline injection. Carrageenan + mS100A9p (1 µg): facial carrageenan 
injection and i.c. injection of 1 µg mS100A9p. Analyzed by one-way ANOVA with Bonferroni 
multiple comparison test. Mice treated with Carrageenan + mS100A9p (1 µg) showed no 
statistical difference from mice treated with Carrageenan + Saline (vehicle) at all times. 
 







The present studies aimed at determining gene expression changes in 
the PFC during inflammatory pain. Gene expression analysis was examined 
in both the left and right prefrontal cortices for the same reasons mentioned in 
the discussion of Chapter 2.1. Analysis of the microarray data revealed 
“immune system process” as the most dominant ontology term based upon 
the lowest Fisher Exact p-value. The increased expression of S100a8, 
S100a9, Lcn2, Il2rg, Fcgrl, Fcgr2b, C1qb, Ptprc, Ccl12 and Cd52 was verified 
by real-time RT-PCR in the ipsilateral and contralateral PFC after facial 
carrageenan injection to either side. S100A8, S100A9 and LCN2 were also 
verified at the protein level by Western Blot analysis, consistent with the 
microarray and real-time RT-PCR results. Immunohistochemistry showed 
increased staining of S100A8, S100A9 and LCN2 in the PFC, compared to 
the controls. Colocalization of S100A8, S100A9 and LCN2 with MPO using 
double immunofluorescence labeling, confirmed the localization of S100A8, 
S100A9 and LCN2 to be in neutrophils. 
S100A8 and S100A9 are members of the S100 family of calcium 
binding proteins, which are highly expressed in neutrophils and monocytes 
(Gebhardt et al., 2006; Soyfoo et al., 2009). They have several pro-
inflammatory functions, including cytokine gene regulation (Sunahori et al., 
2006), arachidonic acid binding / shuttling (Kerkhoff et al., 1999; Kerkhoff et 
al., 2001), and the regulation of endothelial cell integrity (Viemann et al., 2005; 
Viemann et al., 2007). S100A8/S100A9 induces a proinflammatory and 
thrombogenic response in endothelial cells, through the induction of 






proinflammatory cytokines and adhesion molecules. Stimulation of 
S100A8/S100A9 results in loss of cell-cell contacts and increased in 
permeability of endothelial monolayers (Viemann et al., 2005), leading to 
increase leukocyte extravasation during inflammation (Newton and Hogg, 
1998). The finding of high expression of S100A8 and S100A9 in the prefrontal 
cortex after inflammatory pain, induced by facial carrageenan injection is 
consistent with a previous study that showed increased S100A8 and S100A9 
transcripts in the frontal cortex after hind paw inflammation (Mitchell et al., 
2008). Lipocalin 2 (LCN2) is expressed in macrophages (Flo et al., 2004), and 
neutrophils (Bundgaard et al., 1994), and is an important component of innate 
immunity (Flo et al., 2004). Interleukin 2 receptor, gamma chain (IL2RG) is a 
component of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15 is expressed on 
the surface of neutrophils and is critical for the development and function of 
lymphocytes (Habib et al., 2002; Ratthe et al., 2007). The high affinity IgG 
receptor FcγRI (CD64), is expressed on the surface of neutrophils and 
monocytes (Kakinoki et al., 2004) and small-sized neurons (Andoh and 
Kuraishi, 2004), and is implicated in pain (Handwerker et al., 1991). FcγRIIb 
(CD32) is expressed on B lymphocytes (Blank et al., 2005) and regulates the 
function of these cells (Rahman et al., 2007). C1QB is one of the 
heterotrimers of C1q that is involved in the complement cascade of innate 
immune response (Sontheimer et al., 2005) and is expressed in neurons 
(Spielman et al., 2002). Protein-tyrosine phosphatase, receptor-type C 
(PTPRC) is expressed by leukocytes and plays a role in lymphocyte activation 
(Forsyth et al., 1993). CCL12 is expressed on macrophages, and is a potent 






monocyte chemotactic factor that signals through CCR2 (Sarafi et al., 1997). 
CD52 is a cell surface glycoprotein expressed by B and T lymphocytes, 
natural killer (NK) cells, monocytes, and macrophages (Rodig et al., 2006). 
The above-mentioned genes and their products are involved in the regulation 
of inflammatory and immune processes. 
 Genes associated with interferon were also altered after facial 
carrageenan injection. These include alpha-inducible protein 27 (Ifi27), 
interferon induced transmembrane protein 1 (Ifitm1) and interferon induced 
transmembrane protein 3 (Ifitm3). Ifi27 belongs to a family of small, interferon-
alpha-inducible genes of unknown function and was found to upregulate in 
keratinocytes of psoriatic skin (an inflammatory skin disease) (Suomela et al., 
2004). Increased levels of Ifi27 was also detected in blood of patients with 
Sjogren's syndrome, an autoimmune disease (Kimoto et al., 2011). Ifitm1 and 
Ifitm3 belong to a family of interferon-induced transmembrane genes that 
encode cell surface proteins, modulating cell adhesion and influence cell 
differentiation (Tanaka et al., 2005). Increased Ifitm1 and Ifitm3 levels were 
demonstrated in the brain of schizophrenia, which was recently suggested to 
be the consequence of vascular-inflammation (Hanson and Gottesman, 2005; 
Saetre et al., 2007). The involvement of Ifi27, Ifitm1 and Ifitm3 in inflammatory 
diseases suggests that increased expression of these genes in the prefrontal 
cortex may be triggered by facial carrageenan injection induced inflammation. 
In addition, interferons also function to activate immune cells, which may 
explain the increased expression of genes involved in immune system 
process. 






Genes encoding adhesion molecules were increased in the prefrontal 
cortex after facial carrageenan injection. These include alpha 4 integrins 
(Itga4), intercellular adhesion molecule (Icam1), junction adhesion molecule 2 
(Jam2) and claudin 5 (Cldn5). α4-integrins are important adhesion molecules 
known to implicate in the recruitment of peripheral blood mononuclear cells 
(PBMCs) such as lymphocytes and monocytes to sites of inflammation 
(Johnston et al., 1996). It mediates the binding of lymphocytes and monocytes 
to multiple cellular and extracellular ligands such as ICAM-1 that is expressed 
on endothelium (Johnston and Kubes, 1999; Kirveskari et al., 2000). α4-
integrins expressed on neutrophils, mediate neutrophils adhesive interactions 
with endothelium and purified adhesion molecules, and recruit neutrophils 
during inflammatory processes (Johnston and Kubes, 1999). ICAM-1 is an 
adhesion molecule expressed on endothelial cells (Antonelli et al., 2001). It 
plays an important role in immune-mediated cell-cell adhesive interactions, 
and may play a primary role in regulating blood-brain barrier function and 
structure (Huber et al., 2006). ICAM-1 is also involved in regulating 
transendothelial migration of leukocytes, which includes monocytes, 
neutrophils and lymphocytes (Frank and Lisanti, 2008). Likewise, JAM-2 is 
expressed in high endothelial venules and plays important role in the 
regulation of tight junction assembly in epithelial and endothelial cells (Liu et 
al., 2000). Similar to ICAM-1, JAM-2 regulates transendothelial migration of 
leukocytes (Johnson-Leger et al., 2002). Claudin 5 is a transmembrane 
protein that is present in tight junctions of endothelial cells and is a component 
of the BBB (Nitta et al., 2003; Amasheh et al., 2005). Increased expression of 






the above adhesion molecules may enhance transmigration of leukocytes in 
the prefrontal cortex during inflammatory pain. 
Analyses of the effect of perfusion on the expression of the genes 
related to immune process were further carried out. The results indicated no 
significant difference in gene expression between perfused and non-perfused 
PFC at 3 days after facial carrageenan injection. In contrast, a previous study 
demostrated significantly lower spinal levels of S100a8 and S100a9 
transcripts in perfused compared to non-perfused animals, 24 hr after hind 
paw inflammation (Mitchell et al., 2008). A possible explanation is the duration 
of tissue inflammation. In the study by Mitchell et al., leukocytes may still have 
been in the process of undergoing transendothelial migration at 24 hr after 
hind paw inflammation, whereas 3 days after facial carrageenan injection (this 
study) most of the leukocytes could have transmigrated into the tissue. 
Analyses of blood and brain showed that increased expression of some of the 
genes in the PFC were also found in blood i.e. S100a8, S100a9, Lcn2, FcgrI 
and Cd52. This suggests activation of leukocytes at the site of carrageenan 
induced inflammation, and transmigration of circulating leukocytes into the 
brain. On the other hand, increased expression of several other genes i.e. 
Il2rg, Fcgr2b, C1qb and Ptprc was found only in the brain but not blood after 
facial carrageenan injection. This result is suggestive of gene changes being 
either induced in neural cells as a result of increased neuronal activity during 
pain, or genes that are upregulated upon entry of leukocytes into the brain 
and interaction with neural tissues. 






Further work is necessary to elucidate the nature of these potential 
interactions. Nevertheless, it is conceivable that S100A8, S100A9 and LCN2 
with their pro-inflammatory properties could activate the PFC, which might in 
turn trigger the activation of descending inhibitory mechanisms, resulting in 
antinociception. A peptide, identical to the C-terminus of murine S100A9 
protein (mS100A9p), was synthesized and injected at two concentrations into 
the left and right lateral ventricles and the dorsolateral prefrontal cortices at 
peak nociceptive response. Carrageenan-injected mice exhibited a 
significantly reduced withdrawal response 12 hr after administration of 
mS100A9p while control mice were unaffected. In addition, antinociceptive 
effect of mS100A9p was not observed when infused intracortically into the 
barrel somatosensory cortex suggesting the effect of mS100A9p to be specific 
to the prefrontal cortex. However, i.c.v. injection of mS100A9p was found to 
be effective probably because this route of administration infused the whole 
brain which includes the prefrontal cortex. Other studies have also confirmed 
the antinociceptive effects of S100A9 in experimental neuropathic pain, shown 
by a reversal in the signs of spontaneous pain in chronic constriction injury 
(CCI) of rats after treatment with mS100A9p by intraplantar, oral or intrathecal 
route. (Paccola et al., 2008). Intraperitoneal injection of purified S100A9 was 
demonstrated to have an antinociceptive effect in acute inflammatory 
peritonitis induced by glycogen or carrageenan injection in mice (Giorgi et al., 
1998). One explanation is that mS100A9p interferes with mechanisms 
involved in nociception, hyperalgesia and calcium signaling in sensory 
neurons, modulating primary afferent nociceptive signal by inhibiting activation 






of N-type voltage operated calcium channels (Dale et al., 2009). Alternatively, 
it is possible that immune activation by S100A8, S100A9 and LCN2 may 
stimulate the frontal lobe, leading to activation of the descending supraspinal 
pain control system and antinociception. 
Previous microarray study on the brainstem after facial carrageenan 
injection showed 22 genes with greater than 2-fold change. Five genes in 
common were identified between the brainstem and the prefrontal cortex in 
this study. These include Lcn2, Vwf, Icam-1, Ccl12 and suppressor of 
cytokine signaling 3 (Socs-3). Although both the brainstem and prefrontal 
cortex showed upregulation of immune response and proinflammatory genes, 
it is possible that defense / immune cell and endothelial activation in the 
brainstem after facial carrageenan injection could be pronociceptive whereas 
activation of immune cells in the prefrontal cortex may have an antinociceptive 
effect. Moreover, certain genes such as P-selectin were increased in the 
brainstem but not in the PFC. On the other hand, genes such as S100a8 and 
S100a9 were increased in the PFC but not in the brainstem. It is conceivable 
that there are site-specific changes in gene expression that could be exploited 
to provide novel therapeutic options for control of pain. 
Finally, the microarray results in the present study suggest differences 
in the left and right PFC, although an overlap in gene changes was 
attributable to the pain-specific effects discussed above. The difference of 467 
altered genes in the left PFC in contrast to the 194 genes in the right PFC in 
response to a pain-stressor may suggest evidence of functional laterality of 






the PFC. However, further study is necessary to ascertain this finding. In 
conclusion, the present study suggest that immune related genes may play an 
important role in the prefrontal cortex after inflammatory pain, and that 
S100A9 has an antinociceptive role in the prefrontal cortex. 
















Chapter 2.3 miRNA changes of the brainstem & 




















Previous studies on gene expression analyses have demonstrated 
alteration in several genes in the brainstem and prefrontal cortex after facial 
carrageenan injection-induced orofacial pain. Increased expression of 
adhesion molecules-related genes were observed in the brainstem, and 
increased expression of immune system process genes were detected in the 
prefrontal cortex of 3 days post carrageenan-injected mice. While the 
increased expression of these genes may play roles in the process of 
orofacial pain, it is also important to understand the molecules that regulate 
the increased gene expression investigated in chapter 2.1 and 2.2. Therefore 
miRNA was analyzed in the present study to investigate its role in regulating 
gene expression resulting in carrageenan-induced orofacial pain. 
The discovery of miRNAs has broadened our overall understanding of 
the mechanisms that regulate gene expression, with the addition of a new 
level of regulatory control (Bartel, 2004; Jeyaseelan et al., 2008). These small, 
non-coding, single-stranded segments of RNA containing 19 to 24 nucleotides 
are important post-transcriptional regulators that bind to complementary 
sequences on target mRNA transcripts, resulting in translational repression 
and gene silencing (Lee et al., 1993; Bartel, 2004, 2009). Few studies have 
shown changes in miRNA after pain. For example, downregulation of miRNAs 
including miR-10a, -29a, -98, -99a, -124a, -134, and -183 were detected in the 
mandibular division of the trigeminal ganglion, after complete Freund's 
adjuvant induced inflammatory pain (Bai et al., 2007). Decreased expression 
of miR-96, -182, and -183 was also detected in the dorsal root ganglion of rats 






after spinal nerve ligation - a model of chronic neuropathic pain (Aldrich et al., 
2009). 
Currently, little is known about the possible miRNA changes in the 
brain during pain. In view of the importance of the brainstem and prefrontal 
cortex in pain modulation, the present study was therefore carried out using 
microarray-based approaches to identify possible miRNA changes in these 
brain regions which could results in the alteration of gene expression resulting 
in orofacial pain, in a mouse facial carrageenan injection model of orofacial 
pain. 
Minimal miRNA expression changes were observed in both ipsilateral 
brainstem and contralateral prefrontal cortex three days after facial 
carrageenan injection. However, increased expression of mmu-miR-155, and -
223 with > 1.5-fold in the prefrontal cortex were selected for further analysis.  
Both miRNAs were validated by real-time RT-PCR and analyses of these two 
miRNAs shows association with inflammation. Thus, immunohistochemistry 
was carried out using an inflammatory marker to determine the presence of 
inflammation in the prefrontal cortex. Finally, the downstream targets of miR-













2. Materials and methods 
2.1. Experimental animals 
Overall, 40 adult male C57BL/6J (B6) mice were used in the following 
series of experiments, and all procedures performed on these animals were 
as previously described (Chapter 2.1, Section 2.1). 
 
2.2. Facial carrageenan injection 
Treated mice received 50 µl carrageenan (2 mg / 50 µl saline of 
lambda carrageenan, Sigma-Aldrich, St. Louis, MO, USA) subcutaneously into 
the facial region and all procedures performed on these animals were as 
previously described (Chapter 2.1, Section 2.2). 
 
2.3. Assessment of responses to mechanical stimulations 
 Behavioral assessments were carried out in a blinded manner as 
previously described (Chapter 2.1, Section 2.3). 
 
2.4. Microarray data collection and analysis 
2.4.1. Brainstem 
A total of 16 independent samples were used, and none were pooled. 
The samples were divided into four treatment groups and the brainstems 
harvested as previously described (Chapter 2.1, Section 2.4). miRNA 
expression profiles of the tissues were established using mouse miRNA 
microarray, 8 x 15K (Agilent Technologies, CA, USA). Total RNA including the 
miRNA fraction was extracted from the brainstem using the miRNeasy Mini Kit 






(Qiagen, Inc., CA, USA). The amount and purity of the miRNA were examined 
using nanodrop and Agilent 2100 Bioanalyser. Total RNA was 
dephosphorylated, labeled and each sample was hybridized to a single array 
according to standard Agilent protocols. 
The microarray analysis was performed as previously described 
(Chapter 2.1, Section 2.4). The raw data was exported into GeneSpring v11 
software (Agilent Technologies, CA, USA) for analysis, and unpaired Mann-
Whitney Test approach was used to identify differentially expressed miRNAs. 
 
2.4.2. Prefrontal cortex 
A total of 16 independent samples were used, and none were pooled. 
The samples were divided into four treatment groups and the prefrontal 
cortices harvested as previously described (Chapter 2.2, Section 2.4). miRNA 
expression profiles of the tissues were established using mouse miRNA 
microarray, 8 x 15K (Agilent Technologies, CA, USA). The miRNA extraction 
and the microarray experiment were performed as previously described 
(Chapter 2.3, Section 2.4.1).  
The microarray analysis was performed as previously described 
(Chapter 2.2, Section 2.4). The raw data was exported into GeneSpring v11 
software (Agilent Technologies, CA, USA) for analysis, and unpaired Mann-
Whitney Test approach was used to identify differentially expressed miRNAs. 
Databases for miRNA target prediction such as miRBase 
(http://www.mirbase.org/) (Griffiths-Jones, 2006; Griffiths-Jones et al., 2008), 
miRDB (http://mirdb.org/) (Wang, 2008), and TargetScan (integrated into 






GeneSpring v11) (Agilent Technologies, CA, USA) that utilize the miRanda, 
MirTarget2 and TargetScan algorithms respectively were used to predict 
targets of the miRNAs. The mRNAs that are predicted from all 3 databases 
were identified and classified based on their Gene Ontology as previously 
described (Chapter 2.2, Section 2.4). 
 
2.5. Real-time RT-PCR 
2.5.1. MicroRNAs 
RNA samples were reverse transcribed using TaqMan® MicroRNA 
Reverse Transcription Kit (Applied Biosystems, CA, USA). Reaction 
conditions were 16 oC for 30 min, 42 oC for 30 min and 85 oC for 5 min. Real-
time PCR amplification was then carried out in the 7500 Real-time PCR 
system (Applied Biosystems, CA, USA) using TaqMan® Universal PCR 
Master Mix (Applied Biosystems, CA, USA) and miRNA-specific primers and 
probes, mmu-miR-155 (002571, Applied Biosystems, CA, USA) and mmu-
miR-223 (002295, Applied Biosystems, CA, USA) according to manufacturerʼs 
protocols. snoRNA202 (001232, Applied Biosystems, CA, USA) was used as 
an internal control, and all primers and probes were synthesized by Applied 
Biosystems. The PCR conditions and subsequent data calculation were as 
previously described (Chapter 2.1, Section 2.5). The mean was calculated 
and possible significant differences analyzed using Studentʼs t-test. P < 0.05 
was considered significant. 
 






2.5.2. Messenger RNAs 
RNA samples were reverse transcribed and real-time RT-PCR 
performed as previously described (Chapter 2.1, Section 2.5) using the 
following gene-specific primers and probes: C/ebp Beta (Mm00843434_s1, 
Applied Biosystems, CA, USA), GCSF (Mm00438334_m1, Applied 




 Eight adult male C57BL/6J mice were used for this portion of the study. 
Four mice were injected with carrageenan on the left side of the face, and four 
were used as controls. The mice were sacrificed after 3 days and perfused as 
previously described (Chapter 2.1, Section 2.7). The brains were dissected 
out, and blocks containing the prefrontal cortex were sectioned at 20 µm using 
a freezing microtome. The sections were washed in phosphate-buffered 
saline containing 0.1% Triton to remove traces of fixative, and immersed for 1 
hr in a solution of 5% normal goat serum and 1% bovine serum albumin in 
PBS-Tx to block non-specific binding of antibodies. The subsequent steps 
were performed as previously described (Chapter 2.1, Section 2.7), using 
rabbit polyclonal antibodies to myeloperoxidase, MPO (ab9535, Abcam, 
Cambridge, UK, diluted 1:100 in PBS), and biotinylated goat anti-rabbit IgG 
(Vector Laboratories, Burlingame, USA). The region of the PFC examined is 
as previously described (Chapter 2.2, Section 2.7). 
 







3.1. Microarray analysis 
 Facial carrageenan-injected mice showed increasing response 
behaviors to stimulation with the von Frey filament up to the third day after 
facial carrageenan injection, with significantly increased responses compared 
to control mice at post-injection days 1, 2 and 3 (Figure 3.26). They were 
sacrificed on the third day after facial carrageenan injection (time of 
approximate peak nociceptive response), and the ipsilateral brainstems and 




Figure 3.23. Responses to von Frey hair stimulation of the face after facial carrageenan 
injection. (A) Left-sided facial carrageenan injection. (B) Right-sided facial carrageenan 
injection. The Y axis represents number of responses to von Frey hair stimulation of the 
carrageenan injected areas of the face. BI: before injection, 1D, 2D, 3D refer to 1 day, 2 days, 
and 3 days after injection. Control: untreated control. Carrageenan: after facial carrageenan 
injection. Analyzed by Studentʼs t-test. Asterisks indicate significant difference at p-value of 
<0.05 (*), <0.01 (**), and <0.001 (***). 
 
3.1.1. Brainstem 
miRNA expression profiles of the left half of brainstem in mice that 
received left facial carrageenan injection were compared to the corresponding 
data of untreated controls, and a total of 30 miRNAs were altered (p-value < 
0.05). Similarly, miRNA expression profiles of the right half of brainstem in 






mice that received right facial carrageenan injection were compared to data 
obtained from untreated controls, and a total of 12 miRNAs were altered (p-
value < 0.05). No common miRNAs were identified between the differentially 
expressed miRNAs in the left (30 miRNAs) and right (12 miRNAs) halves of 
brainstem (Table 3.7). 
 
miRNA Fold change in left brainstem P-value  miRNA 
Fold change in 
right brainstem P-value 
mmu-miR-153  1.47 0.021 mmu-miR-467a  1.14 0.021 
mmu-miR-19b  1.43 0.021 mmu-miR-28  1.11 0.021 
mmu-miR-101a  1.32 0.021 mmu-miR-133b  1.07 0.043 
mmu-miR-690  1.22 0.021 mmu-miR-22  1.07 0.043 
mmu-miR-192  1.18 0.021 mmu-miR-100  1.07 0.021 
mmu-miR-29c  1.18 0.021 mmu-miR-124*  1.06 0.043 
mmu-miR-154*  1.16 0.021 mmu-miR-322 -1.25 0.043 
mmu-miR-106b  1.16 0.043 mmu-miR-455 -1.21 0.021 
mmu-miR-29a  1.11 0.021 mmu-miR-194 -1.12 0.043 
mmu-miR-15b  1.11 0.021 mmu-miR-592 -1.10 0.021 
mmu-miR-1  1.11 0.043 mmu-miR-467e -1.10 0.021 
mmu-miR-382*  1.10 0.021 mmu-miR-30d -1.10 0.043 
mmu-miR-9*  1.09 0.021     
mmu-miR-185  1.09 0.043     
mmu-let-7g  1.08 0.021     
mmu-miR-361  1.07 0.043     
mmu-let-7i  1.07 0.021     
mmu-miR-103  1.06 0.021     
mmu-miR-151-5p  1.05 0.043     
mmu-miR-128  1.05 0.043     
mmu-miR-138*  1.05 0.021     
mmu-miR-126-5p -1.47 0.021     
mmu-miR-135b -1.25 0.043     
mmu-miR-139-3p -1.23 0.021     
mmu-miR-700 -1.23 0.043     
mmu-miR-378 -1.21 0.043     
mmu-miR-191* -1.20 0.043     
mmu-miR-186 -1.19 0.021     
mmu-miR-296-5p -1.19 0.043     
mmu-miR-541 -1.14 0.021       
Table 3.7. Differentially expressed miRNAs in the ipsilateral brainstems after facial 
carrageenan injection. These are miRNAs that show up- or down-regulation after right-sided or 
left-sided facial carrageenan injection, compared to brainstem specimens of the respective 
sides of untreated mice. 
 






3.1.2. Prefrontal cortex 
miRNA expression profiles of the right PFC in mice that received left 
facial carrageenan injection were compared to the corresponding data of 
untreated controls, and a total of 14 miRNAs were altered (p-value < 0.05). 
Similarly, miRNA expression profiles of the left PFC in mice that received right 
facial carrageenan injection were compared to data obtained from untreated 
controls, and a total of 3 miRNAs were altered (p-value < 0.05). Expression of 
two miRNAs were greater than 1.5-fold, namely mmu-miR-155 and mmu-miR-
223. No common miRNAs were identified between the differentially expressed 
miRNAs in the right PFC (14 miRNAs) and the left PFC (3 miRNAs) (Table 
3.8). 
 
miRNA Fold change in right PFC P-value  miRNA 
Fold change in 
left PFC P-value 
 mmu-miR-223  1.65 0.034  mmu-miR-155  27.24 0.021 
 mmu-miR-135a  1.35 0.034  mmu-miR-451  1.15 0.043 
 mmu-miR-222  1.21 0.034  mmu-miR-150 -1.24 0.043 
 mmu-miR-126-5p  1.19 0.034     
 mmu-miR-138  1.16 0.034     
 mmu-miR-9  1.15 0.034     
 mmu-miR-369-3p  1.14 0.034     
 mmu-miR-139-3p  1.13 0.034     
 mmu-miR-335-3p  1.13 0.034     
 mmu-miR-138*  1.12 0.034     
 mmu-miR-185  1.09 0.034     
 mmu-miR-382  1.09 0.034     
 mmu-miR-26a  1.09 0.034     
 mmu-miR-497 -1.09 0.034       
Table 3.8. Differentially expressed miRNAs in the contralateral prefrontal cortex after facial 
carrageenan injection. These are miRNAs that show up- or down-regulation after left-sided or 
right-sided facial carrageenan injection, compared to prefrontal cortex specimens of the 
respective sides of untreated mice. 
 
 






3.2. Validation of differentially expressed miRNAs by real-time RT-PCR 
The results obtained from the microarray data analysis revealed the 
alteration of miRNAs after facial carrageenan injection. To validate the 
microarray data, the expression levels of miRNAs with greater than 1.5-fold in 
the brainstem and prefrontal cortex were further determined using real-time 
RT-PCR. The differentially expressed miRNAs in the PFC that were chosen 
for validation were mmu-miR-155, and -223. No miRNAs were greater than 
1.5-fold in the brainstem and none were chosen for validation. Besides 
validation of the microarray results of the contralateral prefrontal cortex, real-
time RT-PCR was also carried out to determine if the miRNA changes could 
occur on the ipsilateral prefrontal cortex on the side of the facial carrageenan 
injection. 
 
3.2.1. Contralateral prefrontal cortex 
Real-time RT-PCR was used to validate the results of the microarray 
analyses for miRNAs with ≥ 1.5 fold change. Both mmu-miR-155, and -223 
were validated in the contralateral prefrontal cortex of left-sided facial 
carrageenan injection as well as right-sided facial carrageenan injection. The 
relative fold changes of mmu-miR-155, and -223 in the right prefrontal cortex 
after left facial carrageenan injection were 2.1 and 1.8 fold, respectively 
(Figure 3.27A), while the relative fold changes of mmu-miR-155, and -223 in 
the left prefrontal cortex after right facial carrageenan injection were 2.0 and 
1.8 fold, respectively (Figure 3.27B). 
 







Figure 3.24. Real-time RT-PCR analysis of differentially expressed miRNAs in the 
contralateral prefrontal cortex after facial carrageenan injection. mmu-miR-155, and -223 in 
the mouse prefrontal cortex after facial carrageenan injection. (A) Left-sided facial 
carrageenan injection. (B) Right-sided facial carrageenan injection. Control: untreated control. 
Carrageenan: after facial carrageenan injection. Analyzed by Studentʼs t-test. Asterisks 
indicate significant difference at p-value of <0.05 (*), <0.01 (**), and <0.001 (***). 
 
3.2.2. Ipsilateral prefrontal cortex 
Real-time RT-PCR analyses of the ipsilateral PFC, showed similar 
increases in miRNA expression compared to data established for the 
contralateral PFC. The relative fold changes of mmu-miR-155, and -223 in the 
left prefrontal cortex after left facial carrageenan injection were 1.9 and 1.8 
fold, respectively (Figure 3.28A), while the relative fold changes of mmu-miR-
155, and -223 in the right prefrontal cortex after right facial carrageenan 
injection were 1.9 and 1.8 fold, respectively (Figure 3.28B).  
 
 
Figure 3.25. Real-time RT-PCR analysis of differentially expressed miRNAs in the ipsilateral 
prefrontal cortex after facial carrageenan injection. mmu-miR-155, and -223 in the mouse 
prefrontal cortex after facial carrageenan injection. (A) Left-sided facial carrageenan injection. 
(B) Right-sided facial carrageenan injection. Control: untreated control. Carrageenan: after 
facial carrageenan injection. Analyzed by Studentʼs t-test. Asterisks indicate significant 
difference at p-value of <0.05 (*), <0.01 (**), and <0.001 (***). 






3.3. Inflammation in the prefrontal cortex 
Increased expression of mmu-miR-155, and -223 was found to be 
associated with inflammation. Immunohistochemistry was thus used to 
determine the presence of inflammation in the prefrontal cortex 3 days after 
facial carrageenan injection. A myeloperoxidase (MPO) antibody that stains 
neutrophils was used as a marker for inflammation (Faith et al., 2008). Little or 
no MPO staining was observed in both left and right prefrontal cortices of 
control mice (Figure 3.29A and B, respectively). In contrast, mice that 
received left facial carrageenan injection showed significantly increased in the 
number of MPO-positive cells in both left and right prefrontal cortices (Figure 
3.29C and D, respectively), compared to controls. Higher magnification of the 
MPO-positive cells in both left and right prefrontal cortices is shown in Figure 
3.29E and F, respectively. The increased number of MPO-positive cells in the 
prefrontal cortices of carrageenan-injected mice when compared to control 
mice indicates the presence of inflammation in the prefrontal cortex after facial 
carrageenan injection. 







Figure 3.26. Facial carrageenan injection causes an increase in the number of MPO 
(inflammatory marker) expressing cells in the prefrontal cortex after three days. (A, B) Light 
micrographs of the prefrontal cortex of control mice incubated with MPO antibody. (C-F) Light 
micrographs of the prefrontal cortex of facial carrageenan injected mice incubated with MPO 
antibody. L and R refer to the left (side of facial carrageenan injection) and right (uninjected 
side) prefrontal cortex, respectively. Little or no staining of MPO is observed in the prefrontal 
cortex of control mice (A, B). In contrast, mice that received left facial carrageenan injection 
showed increased numbers of MPO-positive cells in the prefrontal cortex (C-F, arrows), 
compared to controls. The nuclei of cells are labeled green with the methyl green 












3.4. miRNA target prediction of mmu-miR-155, and -223 
 The miRNA targets of mmu-miR-155, and -223 were predicted based 
on three independent miRNA target prediction databases - miRBase, miRDB 
and TargetScan, that utilize the miRanda, MirTarget2 and TargetScan 
algorithms respectively. A list of common targets predicted by all three 
algorithms was compiled to provide an indication of likely potential mRNA 
targets for the differentially expressed miRNAs. By this means, 50 predicted 
targets of mmu-miR-155 (Figure 3.30A) and 30 predicted targets of mmu-miR-
223 (Figure 3.30B) were identified. 
 
 
Figure 3.27. Predicted targets of mmu-miR-155, and -223. (A) Predicted targets of mmu-miR-
155 were identified from miRBase, miRDB and TargetScan databases. 50 predicted targets of 
mmu-miR-155 were in common among these three databases. (B) Predicted targets of mmu-
miR-223 were identified from miRBase, miRDB and TargetScan databases. 30 predicted 
targets of mmu-miR-223 were in common among these three databases. 
 
Predicted miRNAs targets were then classified based on their Gene 
Ontology using DAVID tools analysis. “Cellular process” (34 genes) and 
“metabolic process” (30 genes) are the two major GO-terms for predicted 
targets of miR-155. Other GO-terms include “nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process” (15 genes), “biosynthetic 
process” (14 genes), and “gene expression” (13 genes) (Table 3.9). 







Symbol Target Gene Name Gene Ontology 
Aadat aminoadipate aminotransferase 2,10 
Acta1 actin, alpha 1, skeletal muscle 1 
Aicda activation-induced cytidine deaminase 1,2,3,4,5,6,7,8,9,11 
Cdc73 cell division cycle 73, Paf1/RNA polymerase II complex component, homolog 1,2,3,4,5,6,7,8,9,10,11 
Cdyl chromodomain protein, Y chromosome-like 1,2,3,4,5,6,7,8,9,10,11,12 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1,2,3,4,5,6,7,8,9,10,11,12 
Cyr61 cysteine rich protein 61 1 
Dclre1a DNA cross-link repair 1A, PSO2 homolog 1,2,3,4,5,6,7,8,9 
Det1 de-etiolated homolog 1 1,2,3,4,5,6 
Dnahc9 dynein, axonemal, heavy chain 9 1 
Dync1i1 dynein cytoplasmic 1 intermediate chain 1 1 
Fbxo11 F-box protein 11 1,2,3,4,5,6 
Fgf7 fibroblast growth factor 7 1,2,3,4,10 
Ghr growth hormone receptor 1,2,3,4,7,8,12 
Gpx7 glutathione peroxidase 7 2 
Grhpr glyoxylate reductase/hydroxypyruvate reductase 2 
Hbp1 high mobility group box transcription factor 1 1,2,3,4,5,6,7,8,9,10,11,12 
Hivep2 human immunodeficiency virus type I enhancer binding protein 2 1,2,3,4,5,6,7,8,9,10,11,12 
Jarid2 jumonji, AT rich interactive domain 2 1,2,3,4,5,6,7,8,9,10,11,12 
Lrrk2 leucine-rich repeat kinase 2 1,2,3,4,5,6 
Mier3 mesoderm induction early response 1, family member 3 1,2,3,4,5,6,7,8,9,10,11,12 
Mmd2 monocyte to macrophage differentiation-associated 2 1 
Nfe2l2 nuclear factor, erythroid derived 2, like 2 1,2,3,4,5,6,7,8,9,10,11,12 
Nr5a2 nuclear receptor subfamily 5, group A, member 2 1,2,3,4,5,6,7,8,9,10,11,12 
Pah phenylalanine hydroxylase 1,2,3,4,5,6,7,8,10 
Pcdh9 protocadherin 9 1 
Pkn3 protein kinase N3 1,2,3,4,5,6 
Pld5 phospholipase D family, member 5 2 
Satb1 special AT-rich sequence binding protein 1 1,2,3,4,5,6,12 
Stxbp5l syntaxin binding protein 5-like 1 
Sytl2 synaptotagmin-like 2 1 
Tomm20 translocase of outer mitochondrial membrane 20 homolog 1 
Trim32 tripartite motif-containing 32 1,2,3,4,5,6,12 
Uap1 UDP-N-acetylglucosamine pyrophosphorylase 1 2 
Upp2 uridine phosphorylase 2 1,2,3,4,7,8,9 
Wee1 WEE 1 homolog 1 1,2,3,4,5,6 
Wtap Wilms' tumour 1-associating protein 1,2,3,4,5,6,7,8,9,11 
Zic3 zinc finger protein of the cerebellum 3 1,2,3,4,5,6,7,8,9,10,11,12 
Zmym2 zinc finger, MYM-type 2 1,2,3,4,5,6,7,8,9,10,11,12 
Table 3.9. Gene ontology of mmu-miR-155 predicted targets. 1: cellular process, 2: metabolic 
process, 3: cellular metabolic process, 4: primary metabolic process, 5: cellular macromolecule 
metabolic process, 6: macromolecule metabolic process, 7: cellular nitrogen compound metabolic 
process, 8: nitrogen compound metabolic process, 9: nucleobase, nucleoside, nucleotide and nucleic 
acid metabolic process, 10: biosynthetic process, 11: gene expression, 12: regulation of primary 
metabolic process. 






“Cellular process” (21 genes) and “biological regulation” (17 genes) are 
the two major GO-terms for predicted targets of miR-223. Other GO-terms of 
miR-223 targets include “system development” (11 genes), “organ 
development” (10 genes), “regulation of biological quality” (9 genes), and 
“response to stimulus” (8 genes) (Table 3.10). 
 
Target Gene 
Symbol Target Gene Name Gene Ontology 
Acsl3 acyl-CoA synthetase long-chain family member 3 1 
Acvr2a activin receptor IIA 1,2,3,4,5,6,7,8,9 
Alcam activated leukocyte cell adhesion molecule 1,3,4,5,6,7,8,9 
Cbfb core binding factor beta 1,2,3,4,5,6,7 
Ddit4 DNA-damage-inducible transcript 4 1,2 
Gabra5 gamma-aminobutyric acid (GABA) A receptor, subunit alpha 5 3,11,12 
Galnt7 UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase 7 1 
Igf1r insulin-like growth factor I receptor 1,2,3,4,5,6,7,8,9 
Il6 interleukin 6 1,2,3,4,5,6,7,8,9,10,11,12 
Myh10 myosin, heavy polypeptide 10, non-muscle 1,2,3,4,5,6,7,8,9,10,11,12 
Nfat5 nuclear factor of activated T-cells 5 1,2,3 
Prkar2b protein kinase, cAMP dependent regulatory, type II beta 1,2,3,4,5,6,7,8,9,12 
Ptbp2 polypyrimidine tract binding protein 2 1 
Ptk2 PTK2 protein tyrosine kinase 2 1,2,3,4,5,6,7,8,9,10,11 
Rasa1 RAS p21 protein activator 1 1,2,3,4,5,6,7,8,9,10 
Scn1a sodium channel, voltage-gated, type I, alpha 1,2,3,4,5,10,11,12 
Slc46a2 solute carrier family 46, member 2 1,11,12 
Slc4a4 solute carrier family 4 (anion exchanger), member 4 2,10,11 
Smad1 MAD homolog 1 1,2,3,4,5,6,7,8,9,10,12 
Sp3 trans-acting transcription factor 3 1,2,3,4,5,6,7,8,9,10 
Stim2 stromal interaction molecule 2 1,2,10,11 
Tbc1d16 TBC1 domain family, member 16 2 
Ube2a ubiquitin-conjugating enzyme E2A, RAD6 homolog 1,2,3,4,5,12 
Table 3.10. Gene ontology of mmu-miR-223 predicted targets. 1: cellular process, 2: biological 
regulation, 3: multicellular organismal process, 4: multicellular organismal development, 5: 
developmental process, 6: system development, 7: anatomical structure development, 8: anatomical 
structure morphogenesis, 9: organ development, 10: regulation of biological quality, 11: 










3.5. Targets validation of mmu-miR-155, and -223 
3.5.1. Contralateral prefrontal cortex 
The mRNA levels of a target of mmu-miR-155, C/ebp Beta and a target 
of mmu-miR-223, Sp3 were selected for validation using real-time RT-PCR. 
The relative fold change of C/ebp Beta in the right prefrontal cortex after left 
facial carrageenan injection was 0.5 fold (Figure 3.31A), while the relative fold 
change of C/ebp Beta in the left prefrontal cortex after right facial carrageenan 
injection was 0.6 fold (Figure. 3.31B). No significant change was observed for 
Sp3 (data not shown). 
The mRNA level of a protein downstream of C/ebp Beta, GCSF was 
also determined using real-time RT-PCR. The relative fold change of GCSF 
was 3.4 fold in the right prefrontal cortex after left facial carrageenan injection 
(Figure 3.31A), and 2.2 fold in the left prefrontal cortex after right facial 
carrageenan injection (Figure 3.31B). 
 
 
Figure 3.28. Real-time RT-PCR analysis on targets of mmu-miR-155 in the contralateral 
prefrontal cortex after facial carrageenan injection. C/ebp Beta and GCSF in the mouse 
prefrontal cortex after facial carrageenan injection. (A) Left-sided facial carrageenan injection. 
(B) Right-sided facial carrageenan injection. Control: untreated control. Carrageenan: after 
facial carrageenan injection. Analyzed by Studentʼs t-test. Asterisks indicate significant 
difference at p-value of <0.05 (*), <0.01 (**), and <0.001 (***). 
 






3.5.2. Ipsilateral prefrontal cortex 
 The relative fold change of C/ebp Beta mRNA in the left prefrontal 
cortex after left facial carrageenan injection was 0.6 fold (Figure 3.32A), while 
the relative fold change of c/ebp Beta in the right prefrontal cortex after right 
facial carrageenan injection was 0.5 fold (Figure 3.32B). No significant change 
was observed for Sp3 (data not shown). 
The mRNA level of a protein whose expression is affected by C/ebp 
Beta, GCSF was also determined. The relative fold change of GCSF mRNA 
was 3.4 fold in the left prefrontal cortex after left facial carrageenan injection 
(Figure 3.32A), and 2.9 fold in the right prefrontal cortex after right facial 
carrageenan injection (Figure 3.32B). 
 
 
Figure 3.29. Real-time RT-PCR analysis on targets of mmu-miR-155 in the ipsilateral 
prefrontal cortex after facial carrageenan injection. C/ebp Beta and GCSF in the mouse 
prefrontal cortex after facial carrageenan injection. (A) Left-sided facial carrageenan injection. 
(B) Right-sided facial carrageenan injection. Control: untreated control. Carrageenan: after 
facial carrageenan injection. Analyzed by Studentʼs t-test. Asterisks indicate significant 












The present study was carried out to elucidate miRNA expression in 
the brainstem and prefrontal cortex of mice after facial carrageenan injection. 
The prefrontal cortex contralateral to the facial carrageenan injection was 
chosen for miRNA microarray analysis as nociceptive inputs are transmitted 
to the contralateral somatosensory cortex, and imaging studies have generally 
shown increased activity in the hemisphere contralateral to painful stimulus 
(Hudson, 2000; Usunoff et al., 2006). The left and right halves of brainstems 
of mice that received left and right facial carrageenan injection, respectively, 
showed significant alteration in miRNAs compared to the controls. However, 
the relative fold changes were less than 1.5-fold and were disregarded in this 
study. On the other hand, the right prefrontal cortex of mice that received left 
facial carrageenan injection showed significant increase in mmu-miR-223 with 
1.65 fold compared to the controls. The left prefrontal cortex of mice that 
received right facial carrageenan injection showed significant increase in 
mmu-miR-155 with 27.24 fold compared to the controls. miRNAs with fold 
change ≥ 1.5 were further verified by real-time RT-PCR. 
miR-155 is involved in biological processes including haematopoiesis, 
inflammation and immunity, and is present in myeloid cells, lymphoid cells 
(Faraoni et al., 2009), activated monocytes / macrophages (Taganov et al., 
2006; O'Connell et al., 2007; Tili et al., 2009) and activated mature B and T 
lymphocytes (Rodriguez et al., 2007; Thai et al., 2007; Worm et al., 2009). 
miR-155 functions in the maturation, proliferation and differentiation of myeloid 
and lymphoid cells (Tsitsiou and Lindsay, 2009) and has been identified as a 






component of the primary macrophage response to different types of 
inflammatory mediators (Faraoni et al., 2009). Bacterial lipopolysaccharide 
induces miR-155 expression in human monocytic cell line (Taganov et al., 
2006; Faraoni et al., 2009) and murine macrophages (Tili et al., 2009). 
Inflammatory mediators including cytokine IFN-β, polyriboinosinic–
polyribocytidylic acid (poly IC) or TNF-α also induce miR-155 expression in 
macrophages and monocytes (O'Connell et al., 2007; Faraoni et al., 2009). 
Prediction of miRNA targets was carried out for mmu-miR-155, using 
three different miRNA target prediction databases and algorithms. The results 
showed that majority of miR-155 predicted targets are involved in “cellular 
process” and “metabolic process”, indicating that a single miRNA could 
potentially control the expression of few to several thousands of genes (Pillai, 
2005), which could greatly affect the cellular and metabolic process in the 
system. Analysis on the list of miR-155 predicted targets for potential targets 
likely to be associated with inflammation have lead to the discovery of 
CCAAT/enhancer binding protein Beta (C/ebp Beta). C/ebp Beta, a target of 
miR-155 is involved in the regulation of pro-inflammatory cytokines during 
macrophage activation and the acute phase response (Natsuka et al., 1992; 
Scott et al., 1992). Treatment of murine macrophages with lipopolysaccharide 
strongly induces miR-155 expression, leading to repression of C/ebp Beta 
(Worm et al., 2009). On the other hand, inhibition of endogenous miR-155 
leads to de-repression of C/ebp Beta indicating C/ebp Beta is a target of miR-
155 (Worm et al., 2009). Antagonism of miR-155 using LNA-antimiR results in 
downregulation of GCSF in vitro and in vivo (Worm et al., 2009). Moreover, 






GCSF mRNA level was found to be downregulated by overexpression of 
C/ebp Beta in mouse macrophages (Worm et al., 2009). GCSF is a key 
regulator of granulopoiesis (Watari et al., 1989; Lawlor et al., 2004), which is 
involved in inflammation and also aggravates inflammatory diseases (Eyles et 
al., 2006). It is possible that increased mmu-miR-155 expression after facial 
carrageenan injection could result in repression of C/ebp Beta, leading to 
increased level of GCSF and inflammation in the prefrontal cortex. This was 
verified using real-time RT-PCR, which showed significantly downregulated 
C/ebp Beta and upregulated GCSF. Together, the results provide evidence 
that increased mmu-miR-155 expression after facial carrageenan injection 
could lead to downstream changes, culminating in increased inflammation of 
the prefrontal cortex. 
miR-223 is expressed in the bone marrow which includes 
hematopoietic stem cells and myeloid, erythroid, and lymphoid cells at various 
differentiation stages (Chen et al., 2004). It functions in the maturation, 
proliferation and differentiation of myeloid and lymphoid cells (Tsitsiou and 
Lindsay, 2009) and enhances T-cells and granulocytic differentiation (Chen et 
al., 2004; Sonkoly et al., 2008). miR-223 is also an intrinsic modulator of 
neutrophil sensitivity (Johnnidis et al., 2008). Increased miR-223 expression 
has been detected after spinal cord injury, suggesting a role of miR-223 in 
neuroinflammatory responses after injury (Nakanishi et al., 2009). 
The predicted mRNA targets of mmu-miR-223 were mostly involved in 
“cellular process” and “biological regulation”. One of the possible targets, 






trans-acting transcription factor 3 (Sp3), was found to be inhibited in immune 
cells of patients with multiple sclerosis, a disease caused by inflammation 
(Grekova et al., 2002). It is possible that increased expression of mmu-miR-
223 after facial carrageenan injection may inhibit Sp3 transcription, resulting 
in inflammation of the prefrontal cortex. This possibility was investigated using 
real-time RT-PCR. However, no significant changes were observed in the 
mRNA level of Sp3 after facial carrageenan injection. 
It is possible that increased expression of mmu-miR-155 and mmu-
miR-223 could lead to inflammation of the prefrontal cortex after facial 
carrageenan injection. Immunohistochemistry with antibody to MPO (an 
inflammation marker) showed significantly increased in the number of MPO-
positive cells in the prefrontal cortex of mice that received facial carrageenan 
injection, compared to controls. On one hand, neuroinflammation is known to 
be involved in the development of acute and chronic pain following tissue 
injury (DeLeo and Yezierski, 2001). Conversely, there is also evidence that 
increased activity of the prefrontal cortex may have an antinociceptive effect 
(Wiech et al., 2006; Bar et al., 2007). In conclusion, the present study shows 
that facial carrageenan-induced orofacial pain significantly alters the 
expression of miRNAs in the prefrontal cortex, specifically mmu-miR-155, and 
-223. Increased mmu-miR-155 levels are accompanied by changes in target 
mRNAs, and increased MPO-labeling in the prefrontal cortex. Further studies 
are necessary to determine if specific miRNAs could be useful as therapeutic 
molecules for pain. 




































The brainstem and the prefrontal cortex are known to play important 
roles in pain, and they could be involved in different phases of pain 
processing (Price, 2000; Petrovic et al., 2004). The brainstem is known to 
receive nociceptive information and control the descending spinal systems 
(Besson and Chaouch, 1987; Porro and Lui, 2006), while the prefrontal cortex 
plays an important role in cognitive, attentional, and emotional processing of 
painful stimuli and recruitment of endogenous pain control (Fishman et al., 
2010). Microarray with its powerful and high throughput system was therefore 
used to examine genes expression changes as well as miRNAs expression 
changes in the brainstem and prefrontal cortex in a mouse model of orofacial 
pain.  
At the brainstem level, increased expression of several genes was 
observed in the mice brainstems three days after facial carrageenan injection. 
Of interest were Selp and Icam-1 which were annotated with the GO term 
ʻʻleukocyte adhesion”. They were selected for validation and further analysis. 
The microarray results showed increase expression of CCL12, suggesting the 
release of CCL12 into the bloodstream of the brainstem after facial 
carrageenan injection, attracting leukocytes to the endothelial cells of blood 
vessel. At the same time, inflammation causes upregulation of P-selectin and 
ICAM-1 on the surface of endothelial cells in the brainstem. Both P-selectin 
and ICAM-1 facilitate the transmigration of leukocytes into the brainstem or 
CNS. Leukocytes release pro-nociceptive substances such as nitric oxide, 
superoxide, or peroxynitrite, resulting in orofacial pain (Figure 4.1). Inhibition 
of P-selectin using P-selectin inhibitor, KF38789 demonstrated a decrease in 






pain behavioral response of facial carrageenan injected mice. This blockade 
prevents the binding of leukocytes to P-selectin and ICAM-1, and subsequent 
transmigration of leukocytes into the CNS. Thus, the release of pro-
nociceptive substances into the CNS is inhibited, resulting in reduced pain 
responses - an antinociceptive response (Figure 4.1). 
 
 
Figure 4.1. Diagram showing the process of leukocyte rolling and migration into the tissues, 
facilitated by P-selectin and ICAM-1. 
 
 At the prefrontal cortex level, increased expression of miRNAs i.e. 
mmu-miR-155, and -223 were observed in the PFC 3 days after facial 
carrageenan injection. These miRNAs were associated with inflammatory 






diseases and immune responses. Presence of inflammation was detected in 
the PFC, with increased levels of MPO-positive cells observed in the PFC of 
mice, 3 days after facial carrageenan injection. The possible cause of 
inflammation in the PFC was examined. Facial carrageenan injection resulted 
in the upregulation of miR-155 which leads to decrease levels of its target 
mRNA, C/ebp Beta. The inhibition of C/ebp Beta in turn leads to increase 
GCSF mRNA levels, causing inflammation in the PFC. 
Inflammation in the PFC was also accompanied by increased levels of 
immune response-related genes, including S100a8, S100a9, Lcn2, Il2rg, 
Fcgrl, Fcgr2b, C1qb, Ptprc, Ccl12 and Cd52. This increase in immune 
response may result in activation of PFC, and decrease in pain perception via 
the descending pain inhibitory system (Valet et al., 2004; Xie et al., 2009). In 
addition, S100A9 was demonstrated to have an antinociceptive effect in 
various studies (Giorgi et al., 1998; Paccola et al., 2008). Intracortical injection 
of mS100A9p into the PFC showed a decreased in nociceptive response 12 
hr after administration, suggesting an antinociceptive role of S100A9 in the 
PFC. Together, the increased immune activity and the increased expression 
of S100A9 may contribute to the reduction in nociceptive response in the days 
following the peak nociceptive response (3rd day) (Figure 4.2). 
 







Figure 4.2. Diagram showing possible mechanism of antinociceptive effects facilitated by 
activity in the prefrontal cortex. 
 
 In conclusion, the present studies demonstrated the involvement of 
both brainstem and prefrontal cortex in pain, in a mouse model of orofacial 
pain. The differentially expressed genes in different region of the brain i.e. 
brainstem and PFC could play different roles in pain and contribute to different 
part of the pain system. Five genes in common were identified between the 
brainstem and PFC in this study. These include Lcn2, Vwf, Icam-1, Ccl12 and 






Socs-3. Although both the brainstem and prefrontal cortex showed 
upregulation of immune response and proinflammatory genes, it is possible 
that immune cell and endothelial activation in the brainstem after facial 
carrageenan injection could be pronociceptive whereas activation of immune 
cells in the prefrontal cortex may have an antinociceptive effect. Moreover, 
certain genes such as P-selectin were increased in the brainstem but not in 
the PFC, whereas genes such as S100a8 and S100a9 were increased in the 
PFC but not in the brainstem. It is conceivable that there could be site-specific 
changes in gene expression that could be exploited to provide novel 
therapeutic options for control of pain. 
Future research directions include the use of immunocompromised 
mice that receive facial carrageenan injection and pain behavioral response 
assess over a period of time. Since the brainstem is important in early pain 
response, while the prefrontal cortex seem to be more involved in later 
response, and the current studies suggest that immune activation in the 
brainstem is pro-nociceptive whereas immune activation in the prefrontal 
cortex is antinociceptive. Therefore it is possible that there could be a 
difference in pain behavioral response of the immunocompromised mice, 
compared to wild-type mice. The immunocompromised mice may show a 
decrease in pain response when compared to wild-type mice in the early days 
after facial carrageenan injection due to lack of immune activation in the 
brainstem. However, the immunocompromised mice may show increased 
pain response in later days when compared to wild-type mice as it lack 
immune activation in the prefrontal cortex which can lead to antinociception. 






In addition, the gene expression levels of the genes used in both the 
brainstem and prefrontal studies could be further examined by investigating 
the gene expression levels in days before facial carrageenan injection as well 
as in the days after the injection using real-time RT-PCR. 
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